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ABSTRACT 
AIM: To assess prospectively the role of ambulatory blood pressure monitoring with 
office blood pressure measurement and its correlation with target organ damage in renal 
allograft recipients of Indian Subcontinent 
PATIENTS AND METHODS: Renal allograft recipients were consecutively enrolled to 
study if kidney transplantation normalizes the BP profile. In this study, the relationship 
(concordance or discordance) between blood pressure measured by ABPM compared 
with daytime office BP, and also explored the predictors of diurnal variation, dipping 
profile of BP and left ventricular hypertrophy  in renal transplant recipients. Office and 
ABPM was done in the pre-transplant, 2nd month, 4th month, 6th month and 9th month was 
done along with assessment of laboratory and clinical parameters at each time point. The 
analysis was done using GEE, equivalence study, correlation, multiple linear regression 
two way ANOVA and kappa statistics for agreement. 
RESULTS: 50 renal allograft recipients (M: F=40:10; age 40±11.6 years) were studied. 
Equivalence study for the comparison of times matched measurements for office and 
ABPM showed the upper confidence interval of 5-7units the maximum. At each time 
point the office measurement tend to overestimate the blood pressure by 22-70% for SBP 
and DBP. Pre-transplant 30% patients were dippers. At 9th month post transplant 40% 
patients continued to be dippers at the 9th month while another 40% had become non-
dippers and 20% became inverted dippers. Among the true dippers only one patient 
maintained its dipping status throughout the follow up period.  Among the true non-
dippers at pre-transplant 68%of patients continued to be non-dippers, 24% patients had 
become dippers and 8% patients had become inverted dippers at 9th month after renal 
transplantation. Among the true inverted dippers 66% of patients had become non-dipper, 
16.6% had become dipper and 16.6% continued to be an inverted dipper at the 9th month 
post transplant. Despite a successful renal transplantation and a good control of blood 
pressure 68% of the patients maintained their non-dipping profile at all time points. 
Overall, 6% of the patients improved significantly their circadian rhythm; the non-
dipping profile from 71.8% at pre-transplant was 69% at 9th month of post 
transplantation. Most importantly, the dipping profile in this cohort had improved from 
12.8% at pre-transplant to 16.8% post transplant. Isolated nocturnal hypertension was 
30% which reduced to 2% at 9th month (41.4% of the non-dippers who had nocturnal 
hypertension at pre-tranplant reduced to 3%). Despite a successful renal transplantation 
and a good control of blood pressure, 68% of the patients maintained their non-dipping 
profile through out all the ABPM readings at all time points. There were no predictors for 
control of blood pressure, circadian rhythm and dipping profile. Predictors for LVM, 
LVMI and ∆LVMI were duration of dialysis at pre-transplant, post transplant 
hypertension and number of anti-hypertensive drugs. (p ≤ 0.05)  
CONCLUSION: Majority of the non-dipper dialysis patients maintain a permanently 
abnormal circadian rhythm, despite successful transplant. The blood pressure was 
adequately controlled during the post transplant period irrespective of the number of 
drugs used. Early renal transplant is associated with a highly normal diurnal profile, 
probably related to tacrolimus and aggressive control of blood pressure. However a 
longer duration of follow up is required for a significant improvement of the circadian 
blood pressure and the non-dipping profile.  
 
INTRODUCTION 
In renal transplant recipients, hypertension is common and associated with 
increased cardiovascular and allograft rejection risks.  The limitations affecting office 
blood pressure readings have spurred the development of techniques for measuring blood 
pressure out of a clinical environment. One limitation is poor accuracy of diastolic blood 
pressure (BP) estimates, and the ability of this method to provide only a limited number 
of BP measurements, which can hardly reflect the actual BP load exerted on the heart and 
the peripheral arterial circulation over the 24 hours. The situation is made worse by the 
pronounced variability which characterizes BP and by the frequent emotional impact of 
the physician measuring BP on the reading itself.  
The evidence of the marked variability which characterizes BP in daily life and 
the progressive awareness of the limitations affecting office BP measures have led to the 
increasing use of approaches able to provide information on out-of-office BP, including 
the quantification of its variability over 24 h and an assessment of the overall BP load 
over a given observation period. These techniques include self BP monitoring at home 
(SBPM) and ambulatory blood pressure monitoring (ABPM). 
Though studies of correlation of various modalities of blood pressure monitoring 
with target organ damage in the renal transplantation population have been studied in the 
western population, the conclusions have been varied.  The ideal blood pressure 
measurement and its correlation with target organ damage in the long term follow up of 
hypertension would raise the question of the preferred indicator of overall blood pressure 
burden and hence the risk for that individual. 
OBJECTIVES 
1. To study the role of continous ambulatory blood pressure monitoring in the renal 
transplant population.  
2. To study the correlation of office, and ambulatory blood pressure monitoring in 
the live related renal transplant population. 
3. To study the correlation of the various methods of blood pressure monitoring with 
the graft outcome and target organ damage. 
 
Review of Literature 
 Epidemiology of Hypertension 
 In Asia and India 
National and regional studies of hypertension prevalence have been reported from a 
variety of countries in Asia. The reported range of hypertension varies widely, with a 
prevalence as low as 3.4% in rural Indian Men to as high as 50.1% in Japanese men. 
However, sampling methods, age range of study participants, and blood pressure 
measurement methodology differ between the studies, making direct comparisons 
difficult. Overall, the estimated prevalence of hypertension for men and women, 
respectively, aged 20 years and older is 22.6% and 19.7% in China, 20.6% and 20.9% in 
India, and 17.0% and 14.5% in other Asian countries and islands. 3 
 
Several regional studies have been conducted in different parts of India. However, no 
national studies have been performed.  A recent review on “ the global burden of 
hypertension”, the estimated prevalence of hypertension  (in people aged 20 years and 
older) in India in 2000 was 20.6% among males and 20.9% among females and is 
projected to increase to 22.9% and 23.6% respectively in 2025. Although the prevalence 
of hypertension was approximately 5% in one rural study, the prevalence in most studies 
ranged between 20% and 30% in the urban study. Based on these regional data, it was 
estimated that 60.4 million men and 57.8 million women in India had hypertension in 
2000 and projected to increase to 107.3 million and 106.2 million respectively in 2025. 3, 4 
At an underestimate, there would be 31.5million hypertensive in rural and 34 million in 
urban populations. A total of 70% of these would Stage I hypertension (systolic BP 140-
159 and /or diastolic BP 90-99mmHg). Recent reports that borderline hypertension 
(systolic BP 130-139 and/or diastolic BP 85-89mmHg) and Stage I hypertension carry a 
significant cardiovascular risk and there is need to reduce this blood pressure.3, 4 In India 
and its neighboring countries, awareness level for hypertension is ≤ 45%.5, 6 In one study 
the adequacy of blood pressure control and treatment is only 10%. Thus there is a need to 
increase awareness, detection and adequate control of blood pressure.7  
 
In the West 
The absolute burden of hypertension in the United States has been estimated to affect 65 
million adults,  representing about a 30% increase nationwide from 1988–1994 to 1999–
2000.8 The estimated prevalence of prehypertension is 31%, with 39% of adults > 20 
years noted to be normotensive and 29% hypertensive.9 Thus, approximately 47 million 
individuals in the United States are estimated to be prehypertensive.10  The percentage of 
patients with hypertension receiving treatment has increased from 31 to 59% in the same 
period. However, approximately 30% of adults are still unaware of their hypertension, 
more than 40% with hypertension are not on treatment, and two-thirds of hypertensive 
patients are not being controlled to blood pressure levels < 140/90 mm Hg.12,13 
 
 In Chronic Kidney Disease:  
Hypertension presents a unique problem in patients with chronic kidney disease (CKD) 
since it can act as both a cause of CKD and a significant cardiovascular disease (CVD) 
risk factor more than 50% to 75% of patients with CKD have blood pressure >140/90 
mm.17 Hypertension in CKD increases the risk of several important adverse outcomes, 
including the progressive loss of kidney function leading to kidney failure, early 
development and accelerated progression of CVD, and premature death.17 Hypertension 
results in end-stage renal disease in over 25% of patients requiring renal replacement 
therapies, second only to diabetes mellitus based on United States Renal Data Systems 
(USRDS) data.14 Before the initiation of dialysis, the prevalence of hypertension in CKD 
patients ranges between 75 and 90%, depending on the nature of the underlying CKD, 
and uncontrolled hypertension hastens the progression to end-stage renal disease. 
Hypertension plays a significant role in the high cardiovascular morbidity and mortality 
rate of all CKD patients, but even mild renal dysfunction leads to increased risks for 
mortality.15, 16 
 
In Transplant Population 
Hypertension occurs in up to 60%-80% of kidney transplant recipients.  A large registry 
study showed that recipients with well-controlled blood pressure have improved long-
term survival.17 Smaller; single-center studies also show a relationship with blood 
pressure control and long-term outcome. Although there appears to be a strong 
relationship between hypertension and long-term kidney transplant outcome, there are no 
clinical trials that assess the level of blood pressure control and long-term outcomes.18-21 
 Definition and Classification of Hypertension 
 Definition: The definition of hypertension by all major guidelines continues to be 
systolic blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm 
Hg.10, 22-27  These guidelines also recommend that individuals with chronic kidney disease 
or diabetes be treated to a goal SBP < 130 mm Hg and DBP < 80 mm Hg.10, 22-27 
 
Classification of Hypertension 
It has been suggested that the cutoff for hypertension is best defined as the level of 
arterial BP at which the benefits of intervention exceed those of inaction.  
Over decades the classification has changed as a result of:  
• The decrease in the severity of hypertension over the past half century. 
• The improvement in the efficacy and side effect profile of 
antihypertensive medications. 
• The recognition of the continuum of cardiovascular risk across all levels 
of BP. 
This has resulted in a gradual reduction in the lower limits of target BP for therapeutic 
intervention. 
               Hypertension has been classified based on the new data that has emerged in the 
last 6years in areas of epidemiology, classification of hypertension and management 
strategies.22-26 The final consensus of adopting the Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure 
(JNC 7) has been accepted in the classification, management and research trials in 
hypertension.10  JNC 7 now includes a new designation of “prehypertension” in people 
with blood pressures of 120 to 139 mm Hg systolic and 80 to 89 mm Hg diastolic. 
Although this designation does not provide for a new definition of hypertension, based on 
data from the Framingham Heart Study 28-29, it does identify individuals with a higher 
risk of heart disease and stroke than those with blood pressures below this level, and it 
also identifies those more likely to progress to overt hypertension (> 140/90 mm Hg).  
 
Table 1. Blood Pressure Classification as per JNC VII for Adults Aged 18 Years or 
Older 10 
BP Classification SBP mmHg DBP mmHg 
Normal <120 and <80 
Prehypertension 120-139 or 80-89 
Stage I Hypertension 140-159 or 90-99 
Stage II Hypertension ≥160 or ≥100 
 
The classification of BP is based on the mean of 2 or more properly measured seated BP 
readings on each of 2 or more office visits. In contrast with JNC VI report, a new 
category designated pre-hypertension has been added, and stage 2 and 3 hypertension has 
been combined.10 Patients with prehypertension are at increase risk for progression to 
hypertension; those in the 130/80 to 139/89 mmHg range at twice the risk to develop 
hypertension as those with lower values.31  
 
 
 
Table 2:  Blood Pressure Classification According to Various Guideline Panels  
Classification 
mmHg 
JNC VI 27  JNC VII 10 WHO 25 ESH 23  Canadian 24 
Optimal SBP  <120 
DBP <80 
- - SBP < 120 
DBP< 80 
- 
Normal SBP:120-129 
DBP: 80-84 
SBP < 120 
DBP  < 80 
SBP<140 
DBP< 90 
- - 
Pre-HTN - SBP:120-129 
DBP:80-89 
- SBP 130-139 
DBP 85-89 
- 
High-Normal SBP 130-139 
DBP  85-89 
- 
 
- - - 
Stage   I 
(mild) 
SBP 140-159 
DBP:90-99 
SBP  140-159  
DBP    90-99 
SBP 140-180 
 DBP 90-105 
SBP 140-159 
DBP    90-99 
SBP > 140 
DBP  > 90 
Stage II 
(moderate) 
SBP 160-179 
DBP 100-109 
SBP   ≥ 160 
DBP  ≥ 100 
 SBP  > 180  
DBP >105 
SBP160-179 
DBP100-109 
 
Stage III 
(severe) 
SBP  ≥ 180 
DBP ≥ 110 
- - SBP  ≥180 
DBP≥ 110 
SBP≥ 180 
DBP≥110 
Isolated 
Systolic HTN 
- - SBP >140 
DBP <90  
SBP ≥ 140 
DBP<  90 
SBP≥ 160 
DBP < 90 
 
Circardian  Rhythm of Blood Pressure 
The circadian rhythm of BP was ultimately established by Millar-Craig et al. using 
continuous intra-arterial monitoring.32,33 This study showed that BP was highest mid-
morning and then fell progressively throughout the rest of the day; in addition, the study 
showed that BP was lowest at night (nocturnal dip), but rose before awakening (morning 
surge).33 These findings highlighted the importance of the circadian rhythm of BP with 
regard to the management of hypertension.32,34  
 
 Characteristics of the Circadian Fluctuations in BP that May Lead To 
Harm. 
• Early Morning BP Surge 32, 37 
o In the early morning, BP rises sharply in response to the natural activation 
of the sympathetic nervous system on morning arousal. This early 
morning surge is also associated with other important hemodynamic and 
neurohormonal changes, such as increase in heart rate, vascular tone and 
blood viscosity, and decrease in vagal activity. The activity of the 
sympathetic nervous system appears to be downregulated during the rapid 
eye movement period of sleep, whereas awakening selectively stimulates 
the sympathoadrenal branch of the sympathetic nervous system and 
increases epinephrine levels.   
 
• Loss of the Nocturnal Decline in BP (Non-Dippers) 32,37 
o The natural circadian rhythm of BP includes a nocturnal decrease of 10–
20% in BP.  However, in 25–35% of hypertensive patients a ‘non-dipper’ 
pattern occurs.  
o Non-dipping is arbitrarily defined as present when the night time BP 
reduction is less than 10% compared to the daytime pressure. This blunted 
nocturnal decrease occurs when the natural rhythm of BP is disrupted (for 
a variety of reasons), both in patients with essential hypertension and with 
secondary forms of hypertension.  
o Clinical investigations in patients with hypertension have associated a 
blunted nocturnal BP decrease with increased adrenergic and decreased 
vagal activity during sleep.  
o If there is even a significant nocturnal increase in BP (‘reverse dippers’ 
or ‘risers’ or inverted dippers), a finding that is associated with 
substantial cardiac morbidity.   
o Less commonly, patients may display a larger than usual (42%); 
(extreme dippers dippers), decline in BP during sleep compared with 
wakefulness; this profile of nocturnal BP has been closely associated with 
increased white matter ischemic lesions in the brain and an excessive 
morning BP surge. 
o  At present, knowledge of the circadian profile of an individual patient 
(through ambulatory BP monitoring) aids in identifying increased risk.  
o At this time, there are no data that show that modifying an abnormal 
circadian rhythm leads to improved outcomes. 
 
Clinical Implications of the Circadian Variability of BP 32,37 
 The early morning BP surge period is associated with an increase in the incidence 
of CV events, including stroke and myocardial infarction. Meta-analyses indicate 
that there is a 40% higher relative risk of acute myocardial infarction, a 29% 
increased risk of sudden cardiac death, and a 49% higher relative risk of stroke 
between 0600 h and 1200 h compared with the rest of the day. 
 Loss of the nocturnal decline in BP has been associated with increased risk of 
cardiac, kidney, and vascular target organ injury compared with patients whose 
decline in BP at night is normal, 24 and can be independent of the clinic and 24-h 
mean BP values. Patients with hypertension who exhibit a nocturnal BP increase 
compared with daytime BP (risers) have the worst prognosis for stroke and 
cardiac events. However, there is also some evidence that patients with marked 
nocturnal BP declines (extreme dippers) are at risk of lacunar strokes and silent 
myocardial ischemia.  
 Lurbe and co-workers showed that an increase in night time systolic BP may have 
a key role in the development of diabetic nephropathy. In contrast, patients were 
less likely to progress from normalbuminuria to microalbuminuria if their BP 
decreased during sleep.38 
 
Extrinsic Factors Affecting the Circadian Rhythm of BP  
 Effects of Sleep Quality and Activity 
o The influence of sleep and wakefulness on BP is mediated through 
cyclic variations of the autonomic nervous system.39 in the early 
morning; BP naturally rises sharply in response to activation of the 
sympathetic nervous system upon arousal. Sleep deprivation increases 
sympathetic activity and may disrupt circadian rhythm. 
 
 Dietary influences on the circadian variation of BP  
o Uzu et al. showed that a non-dipper nocturnal BP pattern can be 
converted to a dipper pattern in response to salt restriction in salt-
sensitive patients with hypertension.39  
Normotensive subjects may differ in electrolyte handling and regulation during 
wakefulness, affecting the circadian rhythm of BP. For example, following a period 
of a high potassium diet, a proportion of normotensive African-American adolescents 
switched from non-dipper status to dipper status, with a reversal in nighttime BP 
levels.40 
 
Intrinsic Factors Affecting The Circadian Rhythm of BP 
 Autonomic and Sympathetic Nervous Activity 
o BP increased independently of activity in neurologically intact patients 
with lower spinal cord injuries, but not in patients with sympathetic 
decentralization or higher spinal cord injuries. This sympathetic neural 
activity may contribute to the regulation of BP over the 24-h period.51  
o Higher resting measurements of sympathetic nerve activity were 
associated with greater daytime BP variability and a more marked 
nocturnal decline in BP in healthy normotensive subjects.41 
o However, some suggest that the existence of the non-dipper phenomenon 
may not result from disruption of sympathetic neural activity, but from a 
corresponding decrease in parasympathetic function.42 
 
 Renin-Angiotensin-Aldosterone System 
o The renin–angiotensin–aldosterone system (RAAS), mainly via 
production of angiotensin II, is a key regulator of BP. The RAAS is 
activated in the early morning before arousal as a result of sympathetic 
neuronal activation. 43 
o Both renin and aldosterone demonstrate significant circadian patterns in 
both normotensive and hypertensive individuals,  with peak values 
detected early morning then falling to their lowest point in late evening.43 
 
 Diurnal Variation of BP and Its Disruption in Chronic Kidney Disease 
In the general population, BP falls on average by 10–20% during sleep, a phenomenon 
referred to as ‘dipping’. In about 25% of healthy subjects, and in certain disease states, 
however, a loss of diurnal variation in BP has been reported (non-dipping). Non-dipping 
is particularly common in both children and adults with CKD, and an inverse relationship 
between GFR and the prevalence of non-dipping has been described. The reported 
prevalence of non-dipping in adults with CKD varies, rates of 50% or higher have been 
observed at the earliest stages of disease, whereas rates of more than 80% have been 
observed in patients on dialysis.43,44 
 
 
 
Diurnal Rhythm Variation in Blood Pressure and its Abnormality in 
CKD and Hemodialysis Patient  
  
Figure 1: Normal Diurnal Rhythm  Figure 2:Abnormal Diurnal Rythm 
 
Pathogenesis 
Multiple studies have shown multiple etiologies in the raised blood pressure in CKD and 
hemodialysis patients. No single explanation can be offered for loss of the dipping pattern 
in BP which is an important predictor of target organ damage in this group of patients.37, 
44-51  
However results and conclusion have been varied. The following etiological factors have 
been outlined: 
a. Volume Status  
In non-CKD patients, an association between nondipping and volume expansion has been 
described. In salt sensitive subjects, who tend to be non-dippers, the nocturnal fall in BP 
is significantly increased by a low sodium diet.50 Diuretics can also restore dipping status, 
as evidenced by an increase in the nocturnal fall in systolic and diastolic BP following 
thiazide diuretic administration in patients with essential    hypertension. 50  
A recent study by Narita et al. on 49 hemodialysis patients does support volume 
expansion as an etiologic factor in the genesis of reduced BP variability.46   However, the 
ratio nighttime/daytime BP was significantly higher on the second day.  The ultra 
filtration rate in dippers was significantly less than that in non-dippers and inverted 
dipper.  
In ESRD patients, a statistically significant increase in the night/day ratio and a 
statistically significant decrease in the awake–sleep difference in BP have been reported 
from the first to the second day after dialysis. In a study of 71 unselected hemodialysis 
patients, a trend toward an increased prevalence of non-dipping was also seen that did not 
reach statistical significance.52 However, switching patients from thrice weekly to daily 
dialysis, although effective in reducing BP and extracellular body water, was not found to 
affect dipping status. A high prevalence of nondipping has also been reported in patients 
receiving long, slow home hemodialysis thrice weekly.50 Hence, factors other than 
volume likely also play a role. 
 
b. Autonomic Dysfunction 
Abnormal sympathetic nervous system (SNS) activity has been reported to contribute to 
the non-dipping pattern of BP in non-CKD patients. In healthy subjects, SNS activity 
falls during sleep, as evidenced by a decrease in urinary and plasma catecholamine levels 
and in muscle sympathetic nerve activity (non-REM sleep). In non-dippers without CKD, 
this nocturnal fall in urinary epinephrine and nor-epinephrine levels is diminished. 
 
Spinal injury patients, patients with autonomic syndromes (e.g Parkinsonism-plus, Shy-
Drager), and diabetic neuropaths all have profound alteration in diurnal BP. Uremia is, of 
course, intimately associated with many neurohumoral abnormalities; in essence, there is 
relative excess of sympathetic activity. As increased SNS activity has been described in 
patients with kidney disease, it is possible that loss of diurnal variation in this population 
is due, in part, to abnormal SNS activity as well.53-55 
 
c. Other Factors 
These are factors that are known, to cause and or arise as a complication of kidney 
disease, may also play a role in this diminished nocturnal decline in BP seen in patients 
with renal disease.  
 Diabetes and autonomic dysfunction, operating through increased volume, 
nocturnal SNS activity, or via other mechanisms, are associated with nondipping 
and are prevalent in the CKD and ESRD populations. 
 Low levels of physical activity during the daytime and poor sleep quality have 
been linked to a diminished night time fall in BP.56 
 Sleep apnea, which has been reported in 15% of an unselected group of dialysis 
patients and at higher rates in dialysis patients complaining of sleep problems, is 
associated with nocturnal hypertension. In renal patients, excellent studies have 
shown that obstructive sleep apnea is common and is associated with increased 
sympathetic drive, nocturnal BP, and also left ventricular mass. It is crucial to 
establish whether a continuous pressure airway support intervention will 
successfully reduce these changes.57, 58  
 A smaller decline in nocturnal BP has also been described in treated versus 
untreated hypertensives, possibly owing to the waning effect of antihypertensive 
medications taken in the morning.59 
 A reduction in arterial distensibility has been related to the alteration in the 
circadian rhythm of blood pressure in dialysis patients. It is unknown whether the 
increased pulse wave velocity as documented in a study is at least in part due to 
increased hyper-cellular volume causing an increase in blood pressure and 
increased arterial wall stress.61 
 
Dynamics of Circadian Blood Pressure Profiles in Renal Transplant 
Patients 
In arterial hypertension cardiovascular complications are only loosely correlated to casual 
blood pressure. In contrast, 24-hr ambulatory blood pressure measurements have been 
repeatedly found to be closely related to target organ damage such as left ventricular 
hypertrophy, hypertensive nephropathy and impaired arterial compliance. Furthermore, 
24-hr ambulatory blood pressure measurements allow better detection of trough and peak 
effects of circadian blood pressure fluctuations. Interestingly, those studies in patients 
with primary or secondary hypertension in which a circadian pattern of blood pressure 
was found to be an independent determinant for left ventricular mass also reported an 
inverse correlation between left ventricular mass and nocturnal declines of blood 
pressure. Similar findings have been documented in patients after kidney transplantation. 
 
Immediately following kidney transplantation, nocturnal hypertension (‘‘nondipping’’) is 
common and associated with use of CNIs 60. Over the long term, the nocturnal blood 
pressure profile improves in a significant number of patients (up to 30% in some series). 
The use of cyclosporine post-transplant, however, has been associated with worsening 
nocturnal pressures. 
There is also evidence that kidney transplantation restores the nocturnal decline in BP. In 
a cross-sectional study of 45 renal transplant patients, Gatzka et al found that with 
increasing time from transplant, the number of patients displaying a normal nocturnal 
decline in BP increased. It is evident that the patient inherits the cardiovascular risk of the 
previous situations that is the time spent on dialysis and chronic renal failure stage.62  
 
From above it is clear that the control of arterial hypertension is primordial. ABPM offers 
considerable possibilities for the study of these patients.  
 
Clinical trials though not numerous offer considerable conclusions. As in dialysis patients 
the non-dipper status is of high prevalence in transplant patients as high as 92%. The 
reason for the disruption of the diurnal variation is quite unclear and is a subject of 
discussion. It is not clear that whether this alteration is the cause or alteration in the renal 
damage in the grafts. Few authors are of the opinion that the persistent elevation of 
arterial hypertension is the cause for renal damage while; some are of the opinion that the 
renal damage is the cause for the persistence of non-dipping pattern.62 
 
The underlying renal damage and the immunosuppressive therapy are the cause for the 
persistence of nocturnal hypertension; even though it is uncertain that the cause for the 
same has not been understood. Thus, in the first months of renal transplant, there is a loss 
of normal circadian rhythm and it is after one year more after transplant when dose and 
number of immunosuppressive drugs are less and the graft is generally is functioning 
well do the circadian rhythm come back to normal. In cases where the non-dipping 
pattern exists the functioning of the graft also becomes altered.62,63 
In spite of adequate BP control as validated by clinic BP recordings, majority of the 
transplant patients (78.9%) did not have restoration of nocturnal dipping. This is 
consistent with Farmer’s study63 but at variance with Gatzka et al61 who have reported 
normalization of BP rhythm, post renal transplant. This conflicting literature on post 
transplant BP control needs to be addressed by larger trials as untreated nocturnal non-
dipping of longer duration may accelerate graft dysfunction. 
 
Hypertension in Renal Transplantation 
BACKGROUND 
In the pre-cyclosporine era, hypertension occurred in approximately 40 to 50% of kidney 
transplant patients. The introduction of cyclosporine A has increased the prevalence of 
hypertension in solid-organ transplant recipients and has been reported in 60 to 70% of 
adult renal. 
 
In the recently completed 5-year cadaveric kidney transplant trial comparing tacrolimus 
and cyclosporine, antihypertensive therapy was used in 81% of tacrolimus-treated and 
90% of cyclosporine-treated recipients.64 Although there appears to be a strong 
relationship between hypertension and long-term kidney transplant outcome; there are no 
clinical trials that assess the level of blood pressure control and long-term outcomes. 
RATIONALE: CKD in Kidney Transplant Recipients 
Most kidney transplant recipients have CKD (either kidney damage or GFR <60 
mL/min/1.73 m2 for >3 months). GFR is lower in individuals with a solitary kidney and 
is even lower in kidney transplant recipients because of toxicity from immunosuppressive 
agents used to prevent and treat rejection, such as cyclosporine and tacrolimus. However, 
because albuminuria and abnormalities on urinalysis or imaging studies may not be 
sensitive to tubulointerstitial or vascular damage characteristic of allograft nephropathy, 
it is likely that many kidney transplant recipients will not have markers of kidney 
damage. Patients without markers of kidney damage, but with GFR <60 mL/min/1.73 m2 
will be correctly classified as having CKD. However, patients without markers of kidney 
damage and GFR ≥60 mL/min/1.73 m2 may be incorrectly classified as not having CKD.  
Hence, post-transplant hypertension is a major risk factor for graft survival. It has not 
been established whether this is because of the deleterious effects of hypertension on 
graft structure and function or whether the hypertension is a marker of underlying renal 
disease. Normotension is a good prognostic marker for long-term graft survival.  
The NKF-K/DOQI CKD Guidelines classify kidney transplant recipients without 
markers of kidney damage and with GFR >60 mL/min/1.73 m2 "at increased risk of 
CKD." 
Guidelines for the Classification of Hypertension in Transplant 
Recipients 
Guidelines for target blood pressure in transplant patients have been published. As per the 
NKF-K/DOQI CKD Guidelines the target blood pressure in kidney transplant recipients 
should be <130/80 mm Hg.22 When compared to other guidelines:  
 The American Society of Transplantation guidelines recommend a blood pressure 
target of <140/90 mm Hg.  
 The British Renal Association guidelines recommend a target blood pressure of 
<130/80 mm Hg.  
Since most kidney transplant recipients have low levels of proteinuria, it was the opinion 
of the NKF-K/DOQI Work Group that the level of blood pressure control recommended 
for CVD prevention (<130/80 mm Hg) would be appropriate for slowing kidney disease 
progression.  
In patients with higher levels of proteinuria, a lower blood pressure goal of <120/70 and 
agents that lower proteinuria may be appropriate, as in non-diabetic kidney disease.70 
It was the opinion of the NKF-KDOQI 22 that target blood pressure should be <130/80 
mm Hg, similar to recommendations in diabetic and non-diabetic kidney disease.  
A retrospective analysis of 29,751 kidney transplant recipients with blood pressure values 
at 1 year demonstrated an increased risk of graft loss with each 10 mm Hg increase in 
SBP over 140 mm Hg and DBP over 90 mm Hg.65 In addition, a single-center study of 
long-term kidney transplant survivors with a DBP of 89 to 99 mm Hg had a statistically 
increased rate of GFR decline compared to recipients with lower blood pressure.72 It has 
also demonstrated a graft survival advantage for transplant recipients with lower blood 
pressure readings at 1 year. In another study, the increased risk of graft failure for every 
10 mm Hg increase in SBP was 1.15 (95% CI, 1.02 to 1.30) and for every 10 mm Hg 
increase in DBP was 1.30 (95% CI, 1.05 to 1.61).74 
Pathophysiology of Hypertension in Renal Transplants 
The cause and pathogenesis of post-transplant hypertension is multifactorial. The causes 
of sustained hypertension after renal transplantation are listed below: 
Pathogenesis of Hypertension in Renal Transplantation 
The most common aetio-pathogenesis in renal transplantation will be discussed in this 
review: 
a. Immunosuppression and Hypertension  
Corticosteroids 
The mechanism of steroid-associated hypertension remains incompletely understood and 
is likely multifactorial, involving both expansion of extracellular volume and alterations 
in vascular tone.  
 Expansion of the extracellular volume occurs indirectly in the proximal nephron, 
where glucocorticoids up-regulate angiotensin II receptors and, therefore, enhance 
sodium transport. Glucocorticoids exert a more direct effect on distal sodium 
reabsorption by binding to mineralocorticoid receptors and glucocorticoid 
receptors in the distal convoluted tubule and collecting duct. Both effects are 
potentially modulated by the activity of 11ß-hydroxysteroid dehydrogenase, an 
enzyme that inactivates circulating glucocorticoids, preventing them from binding 
to their receptors, and may be deficient in some forms of essential hypertension.  
 Several mechanisms have been proposed to explain the alteration in vascular tone. 
An indirect increase in vascular tone may occur when glucocorticoids bind to 
glucorticoid receptors and mineralocorticoid receptors on vascular smooth muscle 
cells, leading to up-regulation of adrenergic, vasopressin, and angiotensin II 
receptors and a subsequent increase in the sensitivity of vascular smooth muscle 
cells to catecholamines and angiotensin II.  
 In addition, glucocorticoids may induce changes in vascular smooth muscle cell 
concentrations of sodium, calcium, and, possibly, potassium via down-regulation 
of the Na-Ca exchanger and/or the calcium-dependent potassium channel, leading 
to sodium and calcium influx and subsequent vasoconstriction.  
 Finally, glucocorticoids may down-regulate the expression, synthesis, and/or 
activity of circulating vasodilators such as nitric oxide synthase, prostacyclin, and 
guanylate cyclase activity induced by atrial natriuretic peptide. Glucocorticoids 
may also induce expression of angiotensin-converting enzyme (ACE) in vascular 
smooth muscle cells.75 
 
Attributable incidence of steroid-related hypertension in renal transplant patients 
ranged from 2 to 17% over a follow-up period that ranged from 18 months to 8 
years.76 Attributable incidences was calculated by subtracting the incidence in 
steroid-free patients from the incidence in steroid-treated patients. 
Steroids may have a synergistic effect with cyclosporine in causing hypertension. But 
once the maintenance dose of prednisone has been reduced to <10 mg/day; steroids 
appear to have little if any role in contributing to the genesis of hypertension after 
transplantation 77, 78. Converting from daily to alternate- day steroid therapy while 
maintaining the same total dose significantly reduces the mean arterial pressure 80. 
Steroid withdrawal has been shown to have a beneficial effect on the prevalence and 
severity of hypertension in children and adults 80, 81.  
Calcineurin Inhibitors 
The advent of CNIs (cyclosporine and tacrolimus) has been associated with a dramatic 
rise in the prevalence of hypertension, particularly in solid organ transplant recipients. 
The mechanism of CNI- induced hypertension involves renal, neural, and vascular 
mechanisms that lead to an inability to regulate both volume and renin activity.82 
Cyclosporine and tacrolimus cause functional, dose-dependent, and, typically, reversible 
renal vasoconstriction, primarily by the afferent arterioles.83 As a result, increased 
intraglomerular pressure and a subsequent  reduction in the glomerular filtration rate 
(GFR) lead to sodium and water retention and an eventual increase in blood pressure. 
Repeated ischemic insults of this type may lead to impaired autoregulatory ability. 
Among the mediators most commonly implicated in its pathogenesis, endothelin and 
angiotensin II emerge at the forefront. Other theories include excess sympathetic 
stimulation and decreased effects of vasodilators, such as nitric oxide, natriuretic 
peptides, or prostaglandins.84 
 
Cyclosporine may also cause hypertension by its effects on renal nerves. It has been 
shown that the infusion of cyclosporine into rats increases genitofemoral nerve traffic and 
causes an increase in sodium retention 88. Supportive evidence of the role of renal nerves 
comes from the demonstration that cyclosporine-induced decreases in RBF can be 
mitigated by the denervation of the kidney or by the α1-antagonist prazosin77. The fact 
that renal allografts are denervated could explain why more severe hypertension and 
nephrotoxicity occur in nonrenal transplants as compared with kidney allograft recipients. 
 
However, an alternative explanation for the lower incidence of hypertension in kidney 
transplant recipients may be that kidney transplant programs generally use a lower dose 
of cyclosporine than is used in non-renal transplant recipients. In pediatric renal 
transplant recipients, cyclosporine dose requirements are generally higher than in adult 
patients; this may explain the higher prevalence of hypertension in young kidney 
transplant recipients. 
 
Non-renal mechanisms may also be implicated in cyclosporine-induced hypertension. 
Cyclosporine has a generalized vasoconstrictor effect on smooth muscle and may affect 
the systemic circulation and total peripheral resistance, independent of its effects on renal 
tissue 78, 79. Cyclosporine therapy also results in mild hypomagnesaemia which may 
contribute to hypertension 89 and may also affect intracellular calcium-binding proteins 
which may cause increased vascular tone. 
In patients with stable renal allograft function and cyclosporine blood levels the degree of 
hypertension has been shown to neither abate nor increase over a 3-yr study period 78, 79.  
Chronic Rejection 
In the pre-cyclosporine era, chronic rejection was the most common cause of post-
transplant hypertension. This condition is characterized by progressive deterioration in 
renal function, the development of hypertension and proteinuria and histologic evidence 
of microvascular and tubulointerstitial disease. CNIs may cause structural, and largely 
irreversible, injury to the kidney. Chronically, these drugs induce arteriolar hyalinosis, 
striped interstitial fibrosis, and tubular atrophy, which lead to permanent scarring of the 
parenchyma, chronic sodium retention, and, variably, proteinuria. The result is a volume-
expanded form of hypertension akin to that of chronic kidney disease. The mechanism of 
this chronic toxicity may be related to increased activity of transforming growth factor ß1, 
osteopontin, chemokines, or angiotensin II or accelerated apoptosis in tubular and 
interstitial cells, or it may result from repeated episodes of renal ischemia from acute 
vasoconstriction.80-85 
Decreased nephron number is thought to cause sodium-sensitive hypertension, and this 
may may be one mechanism by which nephron underdosing or early loss of nephrons 
because of rejection contributes to the later development of chronic allograft 
dysfunction.90
Renal Artery Stenosis 
The development of functionally significant transplant renal artery stenosis is 
characterized by an acute deterioration in renal function in association with the sudden 
onset of hypertension or deterioration in preexisting hypertension and the appearance of a 
new bruit over the transplant. Functionally significant renal artery stenosis can be 
diagnosed by the demonstration of a reduction in RBF and GFR after the administration 
of an angiotensin-converting enzyme inhibitor (ACEI); however, the use of this test is not 
valid in patients receiving cyclosporine. 
The development of recurrent or de novo glomerulonephritis or recurrent diabetic 
nephropathy in the transplant may be associated with the development of hypertension; 
although these conditions are not important causes of post-transplant hypertension.  
Renin Mediated Hypertension 
Renin-dependent hypertension may be responsible for persistent hypertension in a small 
percentage of and is likely to persist despite successful transplantation. It can usually be 
controlled with antihypertensive therapy. But in rare cases; it may be the cause of severe 
hypertension after transplantation. Diagnosis may be confirmed by a high native kidney-
to-transplant renal vein renin ratio. If severe, bilateral native kidney nephrectomy91 or 
ablation by embolization 92 has been shown to be effective. It is possible that recurrent or 
de novo essential hypertension may develop after renal transplantation. However, this is 
very difficult to document. The influence of native kidneys on post-transplant 
hypertension usually is attributed to hyper secretion of renin by the native kidneys. Renal 
vein catheterization of host and transplanted kidneys has shown hyperreninemia arising 
from native kidneys, although metabolism of plasma renin activity does not predict 
reliably blood pressure or the response to nephrectomy in transplant patients. 
Likewise, it has been difficult to document an increased prevalence of post-transplant 
hypertension in recipients of cadaveric allografts from donors with a family history of 
essential hypertension 77. However, requirements for antihypertensive therapy have been 
shown to be significantly higher in recipients of cadaver kidneys from donors with a 
history of familial hypertension.  
Correction of Anemia 
Successful transplantation induces a rapid rise in hemoglobin concentration and 
hematocrit. In patients maintained on dialysis rapid correction of anemia frequently is 
associated with exacerbation of preexisting hypertension, the mechanism for which is 
complex but involves a failure of cardiac output to normalize after correction of anemia 
and may be related, at least in part, to persisting extracellular volume expansion, which 
helps to maintain oxygen delivery to the tissues in anemia.90 
Transplanted Kidney 
There is increasing evidence that alterations in renal sodium handling are primarily 
responsible for the genesis of many forms of hypertension and that these abnormalities 
may be transmitted with the kidney by transplantation, indicating that they are intrinsic to 
the kidney itself. In humans, there is evidence from the pre-cyclosporine era that pre-
exisiting essential hypertension in renal transplant recipients could be reversed by the 
receipt of a kidney from a normotensive donor. Retrospective and prospective studies in 
patients not receiving CNIs have shown that kidneys from donors with family history of 
hypertension increase the risk of post-transplant hypertension only in recipients who did 
not have a family history of hypertension. This group of patients (normotensive family, 
hypertensive kidneys) were at more risk of hypertension and suffered a greater degree of 
renal damage during acute rejections than all other recipients.90    
The Different Modalities of Measurement of BP 
In the past 30 years, the techniques for measuring blood pressure to determine whether a 
patient has hypertension have undergone a substantial change. The bulk of our 
knowledge about the risks of hypertension and the benefits of treating it is based on the 
traditional method of taking a small number of readings with the auscultatory technique 
in a medical setting. However, such measurements, which are of enormous value on a 
population basis, often provide a poor estimate of risk in an individual patient for reasons 
such as poor technique of the observer, the “white-coat” effect (the transient but variable 
elevation of blood pressure in a medical setting), and the inherent variability of blood 
pressure. Two techniques have been developed to improve the estimate of true blood 
pressure  ambulatory monitoring and home monitoring (or self-monitoring) 93 
Availability of accurate blood pressure (BP) measurements is a necessary prerequisite to 
reliably assess patients with suspected BP elevation or with established hypertension that 
is to ensure correct diagnosis and management of a high BP condition. It is also an 
essential step to properly determine the need for antihypertensive treatment and its 
efficacy, as well as to estimate the risk of developing BP-related complications. 
Out-of-office blood pressure (BP) measurements such as home or ambulatory BP provide 
important information in the diagnosis and management of hypertension and 
hypotension. This increased use is related to the improved technology of the devices, 
their relatively low cost, the availability of relevant scientific research, and the patient 
acceptance of the methodology.94  
Oscillometry uses small perturbations or oscillations in the cuff that are produced as the 
artery opens to measure BP. The oscillometric devices do not need a stethoscope or 
microphone. Aneroid devices use the deflection of a diaphragm within the meter to 
register BP and generally require a stethoscope.94 
Office Blood Pressure Monitoring (OBP) 
Method of Accurate BP Measurement 
The accurate measurement of BP is the sine qua non for successful management. The 
equipment, whether aneroid, mercury, or electronic, should be regularly inspected and 
validated. The auscultatory method of BP measurement should be used. Persons should 
be seated quietly for at least 5 minutes in a chair (rather than on an examination table), 
with feet on the floor, and arm supported at heart level. Caffeine, exercise, and smoking 
should be avoided for at least 30 minutes prior to measurement. Measurement of BP in 
the standing position is indicated periodically, especially in those at risk for postural 
hypotension, prior to necessary drug dose or adding a drug, and in those who report 
symptoms consistent with reduced BP on standing. An appropriately sized cuff (cuff 
bladder encircling at least 80% of the arm) should be used to ensure accuracy. At least 
two measurements should be made and the average recorded. For manual determinations, 
palpated radial pulse obliteration pressure should be used to estimate SBP; the cuff 
should then be inflated 20 to 30 mm Hg above this level for the auscultatory 
determinations; the cuff deflation rate for auscultatory readings should be 2 mm Hg per 
second. SBP is the point at which the first of two or more Korotkoff sounds is heard 
(onset of phase 1), and the disappearance of Korotkoff sound (onset of phase 5) is used to 
define DBP. Clinicians should provide to patients, verbally and in writing, their specific 
BP numbers and the BP goal of their treatment.10 In spite of its proved clinical usefulness, 
however, such an approach is now acknowledged to suffer from a number of limitations: 
(1) Limited accuracy of diastolic BP estimation (particularly in obese patients, in 
aged patients, in pregnant women, etc.) 
(2) Observer bias and digit preference. 
(3) Alerting reaction (‘white coat’ effect) 
(4) Overestimation of initial BP 
(5) Underestimation of effect of treatment. 
(6) Inability to account for BP variability. 
(7) Limited reproducibility of isolated office readings. (Regression to the mean 
phenomenon). 
One limitation is poor accuracy of diastolic BP estimates, and the ability of this method 
to provide only a limited number of BP measurements, which can hardly reflect the 
actual BP load exerted on the heart and the peripheral arterial circulation over the 24 h. 
The situation is made worse by the pronounced variability which characterizes BP and by 
the frequent emotional impact of the physician measuring BP on the reading itself. The 
latter phenomenon is responsible for a pressor reaction right at the time when the BP is 
taken, leading to an overestimation of the actual BP levels, known as the ‘white coat’ 
effect. 95 
Ambulatory Blood Pressure Monitoring (ABPM) 
Ambulatory blood-pressure monitoring was first described more than 40 years ago.3 The 
currently available ambulatory monitors are fully automatic and can record blood 
pressure for 24 hours or longer while patients go about their normal daily activities. Most 
monitors use the oscillometric technique.  
Ambulatory blood-pressure monitoring provides automated measurements of brachial-
artery pressure over a 24-hour period while patients are engaging in their usual activities. 
Ambulatory blood-pressure monitoring can provide the following three types of 
information, which are of potential value in the clinical field: an estimate of the true, or 
mean, blood-pressure level, the diurnal rhythm of blood pressure, and blood-pressure 
variability. 
The availability of lightweight, quiet, easy-to-wear automated monitors has facilitated the 
collection of large volumes of data (approximately 100 measurements in 24 hours) while 
a subject pursues everyday activities. Data gathered using ABPM have made important 
contributions to our understanding of the pathophysiology of hypertension and its 
complications, the definition of daytime and nighttime normotension, the prognostic 
value of ambulatory BP, and the evaluation of therapy. 
Why is ABPM superior to conventional blood pressure measurement? 
There are a number of obvious advantages: The technique gives more measurements than 
office BP the real blood pressure is reflected more accurately by repeated measurements 
110-112.  
(1) ABPM provides a profile of blood pressure away from the medical environment, 
thereby allowing identification of individuals with a white-coat response110-112.  
(2) ABPM shows blood pressure behavior over a 24-h period during the patient’s 
usual daily activities, rather then when they are sitting in the artificial 
circumstances of a clinic or office;  
(3) ABPM can demonstrate the efficacy of antihypertensive medication over a 24-h 
period, which facilitates more rational prescribing than having to base a decision 
on one or a few office pressure monitoring confined to a short period of the 
diurnal cycle110-112. 
(4)  ABPM can identify patients whose blood pressure does not reduce at night- time 
the non-dippers – who are at greater risk for cardiovascular morbidity110-112. 
(5)  Finally, the technique can demonstrate a number of patterns of blood pressure 
behavior that may be relevant to clinical management – white-coat hypertension, 
hypotension, dipping and non-dipping, etc. 110-112.  
These advantages should have brought ABPM into much wider clinical use many 
years ago. However, this eventuality was delayed because, despite a large body of 
work showing that ABPM predicted outcome on the basis of surrogate markers such 
as left ventricular hypertrophy, microalbuminuria and arterial stiffness, there was 
insufficient prospective evidence to show that ABPM was superior to office BP 
monitoring in predicting cardiovascular mortality. 
Guidelines for Using the ABPM Machine 
 15-30 minutes needed for educating the patient. 
 Patient’s details to be entered 
 Measure BP in both arms: 
o IF SBP difference is <10mmHg, use non-dominant arm 
o If SBP difference is ≥ 10mmHg, use arm with greater pressure. 
 Select the appropriate cuff. 
 Select the frequency of measurement 
 Inactivate the LCD display 
 Give patients written instructions and diary card 
 Instruct patient how to remove and inactivate the monitor after 24hr. 
In clinical practise measurements are made at 20-30min intervals in order not to interfere 
with activity during the day and sleep at night. There should be at least 14 measurements 
of systolic and diastolic measurements during the day and at least seven measurements at 
night; OR else the ABPM should be repeated. 
 
 
 
Use of Ambulatory Blood Pressure in Hypertension Management113 
 Figure 3: Approach to Ambulatory Blood Pressure Monitoring  
 
Self-monitoring of the blood pressure at home and at work can be used to assess whether 
there is a large disparity between the office and out-of-office blood pressures before 
ambulatory monitoring is considered. It is likely that many patients whose self-monitored 
blood pressure is apparently normal will have elevated ambulatory blood pressure and 
Office Blood Pressure 
>140/80mmHg in Low risk patients with no TOD 
>130/80mmHg in High risk patients with TOD 
Self Monitored BP<135/85 Self Monitored BP≥135/85
Initiate Anti-Hypertensive Therapy 
24hr BP <130/80mmHg
24hr BP ≥130/80mmHg
Maintain present therapy.  
Follow up with ABPM every 2 years 
Change antihypertensive therapy to 
improve control for a target of 
<130/80mmHg 
Follow up with ABPM every 
2years 
Perform Ambulatory BP Measurement 
If BP <130/80mmHg 
Follow up no- drug 
therapy for 6-12 months 
and repeat ABPM every 
1-2years 
24hr BP ≥130/80mmHg
Perform ABPM 
would benefit from antihypertensive therapy. For those whose ambulatory blood pressure 
is truly normal (<130/80 mm Hg) despite an elevated office blood pressure and in whom 
there is no evidence of other cardiovascular risk factors or target-organ disease, 
avoidance of unnecessary drug therapy would be a clear benefit of the monitoring 
procedure.113 
Common Patterns of Ambulatory Blood Pressure Monitoring.94 
Figure 4: Normal ABPM-This ABPM suggests normal 24-h 
SBP & DBP (128/78 mmHg daytime, 110/62 mmHg night-
time). 
  
 
 
 
  
 
 
   
Figure 5: White-coat hypertension. This ABPM suggests 
white-coat hypertension (175/95 mmHg) with otherwise 
normal 24-h systolic and diastolic blood pressures (133/71 
mmHg daytime, 119/59 mmHg nighttime). 
Figure 6: White-coat effect. This ABPM suggests mild 
daytime systolic hypertension (149 mmHg), borderline 
daytime diastolic hypertension (87 mmHg), borderline 
night-time systolic hypertension (121 mmHg) and normal 
night-time diastolic blood pressures (67 mmHg) with white-
coat effect (187/104 mmHg).
Figure 7: Systolic and Diastolic hypertension. This 
ABPM suggests mild daytime systolic and diastolic 
hypertension (147/ 93 mmHg), but normal night-time 
systolic and diastolic blood pressures (111/66mmHg) 
  
 
  
 
 
 
 
Recommendations for Ambulatory Blood Pressure Readings 
Currently, an average daytime ABPM of less than 135 mmHg systolic and 85 mmHg 
diastolic is generally considered normal, but even lower values are being advocated 
particularly in high-risk groups, such as diabetic patients, in whom values less than 
130/80 mmHg are considered optimal.94 
A prospective study from Japan has demonstrated that ABPM has a prognostic value, and 
that reference levels can be derived from long-term cardiovascular mortality114.  
The evidence coming from cross-sectional and current longitudinal studies supports 
lower levels of normality for ABPM, although the levels to be targeted by treatment 
remain to be established. 
Figure 8: Isolated systolic hypertension. This 
ABPM suggests severe 24-h isolated systolic 
hypertension (176/68 mmHg daytime, 169/70 mmHg 
Figure 9: Hypertensive dipper. This ABPM suggests 
severe daytime systolic hypertension (181 mmHg), 
moderate daytime diastolic hypertension (117 mmHg) 
and normal night-time systolic and diastolic blood 
pressures (111/68 mmHg). 
Figure 10: Hypertensive non-dipper. This ABPM 
suggests severe 24-h systolic and diastolic hypertension 
(210/134 mmHg daytime, 205/130 mmHg night-time). 
Table 4: Recommended levels of normality for ambulatory blood 
pressure   measurements in adults94 
 OPTIMAL NORMAL ABNORMAL 
AWAKE <130/80 <135/85 >140/90 
ASLEEP <115/65 <120/70 >125/65 
 
Table 5:Ranges for definitions used in the Ambulatory Blood Pressure Monitoring94 
 HYPERTENSION 
 Low Normal Borderline Mild Moderate Severe 
Day Time  
SBP <100 100-135 136-140 141-155 156-170 >170 
DBP <65 65-85 86-90 91-100 101-110 >110 
Night Time  
SBP <90 91-120 121-125 126-135 136-150 >150 
DBP <50 51-70 71-75 76-85 86-100 >100 
 
Ambulatory BP values are usually lower than clinic readings. Awake hypertensive 
individuals have an average BP of 135/85 mm Hg and during sleep, 120/75 mm Hg. The 
level of BP measurement using ABPM correlates better than office measurements with 
target organ injury. ABPM also provides a measure of the percentage of BP readings that 
are elevated, the overall BP load, and the extent of BP fall during sleep. In most people, 
BP drops by 10 to 20% during the night; those in whom such reductions are not present 
appear to be at increased risk for cardiovascular events. In addition, it was reported 
recently that ABPM patients whose 24-hour BP exceeded 135/85 mm Hg were nearly 
twice as likely to have a cardiovascular event as those with 24-hour mean BPs less than 
135/85 mm Hg, irrespective of the level of the office BP.10 
 
 Ambulatory Blood Pressure Monitoring in Renal Transplantation. 
The prevalence of arterial hypertension in renal transplantation is approximately 60-80% 
and is usually associated with left ventricular hypertrophy the pathogenesis being 
multifactorial. Although renal function can improve with renal transplantation there is a 
component of some degree of renal failure, and immunosuppressive therapy that can 
exacerbate hypertension along with other risk factors as mentioned above. Studies have 
been published which state that the ABPM is far more superior than the casual BP in its 
relation to the graft function and its survival115. A rigorous BP control by ABPM appears 
to be mandatory for the graft survival. Similar to patients on dialysis the non-dipper 
status approximately 90% is prevalent in the transplant population. The increase in the 
ambulatory blood pressure during the nocturnal period has been related to the target 
organ damage and with greater risk of cardiovascular mortality.  
 
In a study of 241 patients on the diurnal variation of blood pressure by ABPM done by 
Hayadar et.al showed that there were four correlates of SBP diurnal variation (the ratio of 
the asleep to awake SBP). These were age, renal function (creatinine and GFR), 
cyclosporine level, and the ABPM-TX(ABPM and Transplant interval time). The first 
three parameters had a direct relation with diurnal BP, but ABPM-TX had an inverse 
relationship (i.e., the diurnal variation improved as the time from transplantation 
increased). However, correcting for the confounding effect of each risk factor on the 
other it showed that cyclosporine level and ABPM-TX interval were dependent on the 
presence of one another or did not affect diurnal variation. Only age and GFR were the 
truly independent predictors of diurnal BP variation.116 
The rates of concordance and discordance between casual BP and ABPM-derived BP 
were 80.6% and 19.4%, respectively116, as opposed to 63% concordance in a study of 27 
renal transplant pediatric patients117. In addition, 21% of patients had isolated sleep-
related hypertension that was not screened using office or ambulatory daytime BP.116 
 
 It was concluded by Hayadar et.al that reliance solely on office BP would result in failure 
to diagnose hypertension in 15% of renal transplant patients. This is why ABPM is a 
valuable adjunct in the management of post renal transplant cardiovascular risk 
assessment and treatment.116 
 
Gatzka et al. in 1995, who followed 45 renal transplant patients and showed that as time 
elapsed from transplantation, the diurnal BP variation increased (returned toward normal) 
regardless of the immunosuppressive agents used 62. This was contradictory to the 
subsequent studies that followed by Hayadar et.al116 and Kooman et.al118 who concluded 
that the only independent predictors of diurnal variation of blood pressure were age and 
GFR. 
A prospective study to demonstrate the prognostic superior value of 24-hr ambulatory 
blood pressure over casual blood pressure in patients after kidney transplantation  
indicated that 24-hr ambulatory blood pressure profiles, serum creatinine levels, and the 
age of kidney donor are strong determinants of graft function after transplantation. When 
patients were divided into three similarly large groups according to their 24-hr mean 
arterial blood pressure, those in the upper tertile with a mean arterial pressure ≥97 mmHg 
had higher serum creatinine levels at 6 and 18 months after renal transplantation. Control 
of confounding cofactors that are known to potentially influence renal function in 
transplant recipients such as HLA mismatch, cold and warm ischemic time, organ size, 
immunosuppressive therapy, CMV constellation, and other cardiovascular risk factors did 
not differ between groups of tertiles. However, patients in the upper tertile with the 
highest serum creatinine levels were recipients of grafts from older donors.115 
 
On long term follow up it was noticed casual blood pressure was not related to graft 
function after transplantation, leading to the conclusion that ambulatory blood pressure 
confers a more precise prognostic marker for graft survival than casual blood pressure 
measurements. Patients in the upper tertile of mean 24-hr ambulatory blood pressure had 
a higher rate of renal graft failure than those with a lower 24-hr ambulatory blood 
pressure.115  
 
The link of chronic kidney graft failure with recipient blood pressure has been 
impressively demonstrated in the Collaborative Transplant Study. The greater the blood 
pressure post transplantation the less favorable was the long-term kidney graft outcome in 
the study cohort of 29,751 patients119. Arterial hypertension presents a major risk factor 
for renal allograft survival. However, in all these studies only casual blood pressure was 
measured which is not as closely related to the degree of target organ damage as 24-hr 
ambulatory blood pressure readings120-124. 
A prospective study of 1700 Danish men and women, aged 41 to 72 years, without major 
cardiovascular diseases showed that ambulatory BP provided prognostic information 
about cardiovascular disease better than office BP. Isolated office hypertension was not a 
risk factor and isolated ambulatory hypertension tended to be associated with increased 
risk of target organ damage. A blunted BP decrease at night was a risk factor in subjects 
with daytime ambulatory hypertension.127 
  
Office BP measurements may offer only a spot quantification of the BP load in a given 
individual. Their reliability may increase with repeated measurements, a practice that 
should be reinforced among physicians. Even in cases of repeated assessment, however, 
office BP measurements are unlikely to provide an assessment of BP behavior in daily 
life, an assessment which can be obtained by out-of-office BP monitoring through either 
monitoring BP at home or 24-h ABPM.  
 
These observations indeed carry a number of important clinical implications. 
(1) A significant proportion of untreated and treated hypertensives, apparently not 
controlled in the office, are actually controlled out of the office and their cardiovascular 
risk assessment based only on office BP largely overestimates their real risk.  
(2) A significant proportion of untreated and treated hypertensive patients, apparently 
well controlled in the office, are actually uncontrolled out of the office and their 
cardiovascular risk assessment based exclusively on office BP largely underestimates 
their real risk.95 
Prakash et.al concluded form a study of CKD patients including transplant recipients and 
hemodialysis patients that in spite of adequate BP control as validated by clinic BP 
recordings, majority of transplant patients (78.9%) did not have restoration of nocturnal 
dipping. With regard to BP control the DBP and SBP evaluation at 1 month, there was no 
difference in daytime and nighttime SBP and DBP in both survivors and non-survivors. 
However, at 6 months the non-survivors had significantly raised daytime and nighttime 
DBP and SBP. This was an important predictor of mortality in their group of patients. 
This persistently raised BP load, was an important predictor of mortality. They also found 
that a significant higher SBP, attenuation of nocturnal dipping, more LVH (left 
ventricular hypertrophy) and left ventricular mass index (LVMI) in the non-survivors as 
compared to survivors. Not withstanding the fact that anemia is strong predictor of LVH 
and other cardiac complications; an elevated SBP was more important in the causation of 
LVH and adversely affecting the survival of patients. In their study, nocturnal non-
dipping was associated with increased mortality as 80% of non-survivors were non-
dippers. Conversely, 55% of the survivors were non-dippers and 45% were dippers.128 
 
Verdecchia et.al confirmed that ambulatory BP is more closely related to LV muscle 
mass than is casual BP. The most important finding, however, of this study was the 
inverse relation between nocturnal BP decline and LV muscle mass in a large population 
of unselected and untreated patients with essential hypertension. Only nighttime 
ambulatory BP disclosed a very evident differentiation between the two hypertensive 
groups. The findings of this study support the concept that the duration of exposure to 
increased levels of BP and wall stress over the 24 hours can play an important role in the 
pathogenesis of LVH in unselected patients with arterial hypertension. In these patients, a 
nocturnal reduction of systolic and diastolic BP by more than 10% of daytime values can 
exert the beneficial effect of delaying or preventing development of cardiac LVH.130 
 
In the study by Devereux et al131, the correlation coefficients between casual or 
ambulatory BP and LV mass index were generally lower, and in that by Drayer et al 132, 
generally higher. Both in the study by Devereux et al and in that by Drayer et al, daytime 
BP showed a generally closer relation to LV mass than did nighttime BP.  
 
In the study by Rowlands et al, 133 awake BP and sleep BP correlated equally well with 
LV mass, whereas in another study performed on a mixed population of hypertensive and 
normotensive patients, sleep BP showed a closer relation to LV mass than did awake BP. 
 
Correction of the uremic state by renal transplantation leads to complete resolution of 
systolic dysfunction, regression of LVH, and improvement of left ventricular dilatation. 
In fact the reduction of LVH was dependent on adequate renal function and on a decrease 
in the systolic pressure levels not with diastolic blood pressure levels. LVH reduction was 
dependent on adequate renal graft function and systolic pressure levels registered by 
ABPM after transplantation. Renal transplantation had a beneficial impact on the uremic 
patient’s cardiomyopathy, whether it manifested as LVH, left ventricular dilatation, or 
systolic dysfunction. ABPM detected a high prevalence of persistent hypertension and 
non-dippers in these patients and was a strong predictor of LVH.134 
 
Cuspidi et.al in a study of 611 patients concluded; firstly the classification of isolated 
clinical hypertension based on a single ABPM reading has limited short term 
reproducibility. Secondly, repeated ABPM measurements should be recommended to 
correctly diagnose patients with isolated clinical hypertension and improve 
cardiovascular risk stratification.136 
 
Jokinitty et.al, in his prospective study to evaluate the predictors of LVM and change of 
LVM of a period of ten years concluded that ambulatory blood pressure improved the 
prediction of LVM than office blood pressure measurement. Secondly, the pulse pressure 
was the most significant blood pressure parameter in predicting the future LVMI and 
change in LVMI.138-140 
 
Mean arterial blood pressure after renal transplantation had no significant impact on risk 
of cardiovascular disease (and patient death). Pulse pressure, as marker for vascular 
stiffness, was a risk factor for both cardiovascular events and mortality in renal transplant 
patients, as already has been demonstrated in the general and renal transplant 
population.139, 140 
 
Therefore, the available data do not allow drawing definite conclusions about the possible 
predominance of daytime or nighttime BP on LVH development in hypertensive patients. 
A constant finding in these studies; is the generally closer relation of systolic over 
diastolic BP to the degree of hypertrophy, another evidence that wall stress, which is 
mostly related to systolic BP, is a key factor influencing LVH development. 
A personal history of cardiovascular disease before transplantation is a strong risk factor 
for cardiovascular events after transplantation. The duration of renal replacement therapy 
before transplantation had an important negative impact on cardiovascular events in our 
experience, corroborating the advantages of preemptive transplantation.140 
The intake of steroids was one of the most significant detrimental factors. In this study, 
most of the patients without steroids either stopped corticosteroids 1 year after 
transplantation because they had a low immunological risk or entered randomized trials 
that evaluated the impact of avoiding corticosteroids143. Steroid-free patients showed a 
significant reduced risk of dying or developing cardiovascular events than patients 
continuing steroids. 
The development of de novo diabetes mellitus also was shown to have a strong negative 
impact on cardiovascular events (and patient survival), reinforcing available data144. The 
importance of renal dysfunction and risk of death and cardiovascular events has recently 
been stressed in the general population and after myocardial infarction 145,146.  
After renal transplantation, serum creatinine at 1 year or at baseline has been shown to be 
a strong risk factor for cardiovascular death.147 
 
Direct, independent association of cardiovascular risk with observed ambulatory blood 
pressure (BP) and inverse association with the degree of BP reduction from day to night 
have been established. Daytime and nighttime mean BP, the difference between daytime 
mean and nighttime mean BP, 24-hour mean pulse pressure, and early-morning BP surge 
derived from ambulatory blood pressure monitoring (ABPM) data allow the identification 
of high-risk patients. Although ABPM should not be routinely used for the diagnosis of 
hypertension, its use to identify white coat hypertension is particularly appropriate to 
avoid unnecessary use of antihypertensive therapy. 
 
Data generated by ABPM have established that, even after adjustment for established risk 
factors, there is a progressive increase in the risk of cardiovascular morbidity and 
mortality with elevated 24-hour, daytime, and nighttime BP. Also, studies in older 
Japanese subjects have shown the importance of the early-morning BP surge on target 
organ damage. The technique of ambulatory BP measurements has become widely 
adopted to identify effective therapeutic options that provide BP control throughout the 
dosing interval. Emphasis in the future may focus on the ability of drugs to control the 
morning BP surge, thereby helping to optimize the control of cardiovascular disease. 
 
In the primary care setting, the contribution of ABPM to the management of hypertensive 
patients is increasingly acknowledged. Whereas in the past, this technology was 
considered “experimental,” this has changed recently with improved insurance coverage 
for performing ABPM in specific patients and support for its use in certain subgroups of 
hypertensive patients by both the Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure10 and by the 
Council on High Blood Pressure Research of the American Heart Association.153 
AIM 
1. To study the role of ambulatory blood pressure monitoring in the renal transplant 
population.  
2. To study the correlation of office, and ambulatory blood pressure monitoring in 
the live related renal transplant population. 
3. To study the correlation of the various methods of blood pressure monitoring with 
the graft outcome and target organ damage. 
PATIENTS AND METHODS 
STUDY DESIGN AND LOCATION: This prospective study was conducted at the 
department of Nephrology, Christian Medical College, Vellore. Patients who underwent 
renal transplantation from March 2007 to February 2008 were followed up to January 
2009. 
INCLUSION CRITERIA 
• Renal allograft recipients.  
• Completed 9 months of follow up. 
• Male or female subjects ≥18 years 
 
EXCLUSION CRITERIA 
• Pediatric transplantations are avoided as they have different cutoffs for BP control 
based on the age group. 
• Incomplete follow up 
• Graft Failure with return to dialysis during the study period. 
• Patient death prior during the study period. 
 
METHODOLOGY 
PATIENTS:  50 consecutive Renal Allograft recipients who underwent renal 
transplantation, satisfied the inclusion and exclusion criteria were followed up for 9-
12months. Pre-transplant, five patients had a pre-emptive transplant, 44patients were on 
hemodialysis and one patient was on continues ambulatory peritoneal dialysis. 27patients 
received simulect induction 6 patients received anti-thymocyte induction and 17 patients 
received no induction. 49 patients received immunosuppresion of Prednisolone, 
Tacrolimus and Mycophenolate Mofetil and one patient received Cyclosporine, 
Prednisolone and Mycophenolate Mofetil in view of a positive hepatitis C serology. 
 
STUDY DESIGN:  Baseline evaluation was performed prior to transplantation. Study 
procedures included measurement of casual and 24-hr ambulatory blood pressure, a 
routine laboratory work-up, ultrasound of renal allograft, and a two-dimensional guided 
M-mode echocardiography was done. Further visits throughout the 9months follow-up 
period were performed at 2nd, 4th, 6th and 9th month of transplantation and included 
laboratory tests, casual blood pressure measurements, ambulatory blood pressure 
measurement and an echocardiography at 9th month. 
 
BLOOD PRESSURE MEASUREMENTS 
Office Blood Pressure Measurement Protocol 
A total of three office blood pressure measurement was taken by a trained doctor 
according to the suggestions of the World Health Organization (WHO). Blood pressure 
measurements were performed with a standard sphygmomanometer in a sitting position 
after 10 min of rest with cuff size adjusted according to the individual‘s arm 
circumference. Timed measurements of casual blood pressure were taken during the 
initiation and termination of the ambulatory blood pressure measurement.  
 
Ambulatory Blood Pressure Monitoring Protocol. Blood pressure was recorded non-
invasively with a commercially available device Welch Allyn ABPM 6100 Ambulatory 
Blood Pressure Monitor over 24 hr on a regular working day. Each recording started at 
9am and ended 9am the next day. 24hr-readings were taken at an interval of half hour 
during the day and night. The patients were asked to maintain a diary to document the 
time the went to asleep and awoke. Blood pressures were obtained in the non-dominant 
arm however in the presence of an arteriovenous fistula the cuff was applied on the other 
arm. Ambulatory blood pressure values given in the tables reflect the timed measurement 
of blood pressure with the office blood pressure. From the blood pressure monitors data, 
mean BP while awake, mean BP during sleep and mean 24 hr BP and pulse rates were 
derived. ABPM derived BP levels were reported to normal standards, derived from large 
populational studies.  
 
ABPM hypertension was defined as following: daytime BP>135/85; nighttime BP > 
120/75; 24hrs. BP>130/80 155.  Normal circadian rhythm was defined as a sleep-to awake 
BP ratio>0.92 (systolic BP) and >0.90 (diastolic BP); these values were taken from a 
normal population from the study of Staessen et al.156   Patients were classified as Dipper: 
0.8-0.9, Non-dipper: 0.9-<1, Inverted dipper: >1 155-156 SBP diurnal variation was defined 
as average asleep-awake SBP. A high morning surge was defined if more than >20% of 
the mean a 24hr ABPM were ≥ 135/85.  Casual hypertension was defined as office BP 
greater than 140/90 mm Hg.25 Hypertension by ABPM was defined on the basis of 
average daytime measurements of SBP greater than 135 mm Hg and diastolic BP (DBP) 
greater than 85 mm Hg; or nighttime SBP greater than 125, DBP greater than 75 mm Hg, 
or both.94   The protocol was approved by the Clinical Investigation Ethics Committee 
and Institutional review board of the institution. 
 
Echocardiography: It was performed with commercially available Philips equipment 
(model: iE 33), with a 2.5-mHz mechanical transducer.  
             The following structural parameters were evaluated: interventricular septal 
thickness in systole; interventricular septal thickness in diastole; left ventricular end 
systolic diameter (LVESD); left ventricular end diastolic diameter (LVEDD); left 
ventricular posterior wall thickness in systole; left ventricular posterior wall thickness in 
diastole; LVM; left ventricular mass index and (LVMI) estimated by the ratio between 
the LVM and body surface area.  
 
The LVM was calculated by the modified formula of the American Society of 
Echocardiography: 131,158,159 
LVM= 0.80{1.04(LVEDD +ISTD+LVPWTD)3-(LVEDD)3}+0.6 
LVH was defined as a LVMI value greater than 134 and 110 g/m2 for men and women.160  
The percentage variation (∆) of the LVMI before and 12 months after transplantation was 
also calculated:  
Delta (∆) = LVMI pre-transplant-LVMI post transplantation/ LVMI pre-
transplantation*100 158,159 
 
Laboratory work-up: All renal transplant recipients underwent a routine laboratory 
work-up at least every point of the visit after kidney transplantation which included urine 
analysis, serum creatinine, serum urea, serum uric acid, serum electrolytes, Cyclosporine 
levels, Tacrolimus and Mycophenolate levels,  and complete blood cell count. eGFR was 
calculated using the abbreviated MDRD formula. 
 
Statistics:  Descriptive statistics was used to describe the demography, clinical, 
laboratory characteristics, office and ABPM registries. A repeated measure of ANOVA, 
logistic regression and paired‘t’ test was used for the comparison of the various variables 
accordingly.  
 
Bland Altman plot was plotted over time for CABP (2nd, 4th, 6th month post transplant) 
against mean difference of office-CABP for both SBP and DBP. Error bars with 95% 
confidence interval was plotted over time for SBP and DBP against the number of dugs 
and over time. The following risk factors were considered for the GEE analyses: weight, 
BMI, casual BP, laboratory variables, ABPM registries, and office BP to identify 
predictors for good control of blood pressure.   
 
All analyses were performed using a SPSS 16.0 and SAS 9.1 and STATA 10.0 Statistical 
methods included: linear regression, repeated measure Chi-square, t-testing, all with two-
tailed significance. However, the Blood Pressures measured over time (baseline, 2, 4, 6 
months) were analyzed using Generalized Estimating Equations (GEE) method, where 
the individual level correlations (repeated measures) were identified using Quasi 
Information Criteria (QIC) and the correlation structure was adjusted in the analyses.  
The Statistical Analyses System (SAS) 9.1 software was used to do the above method.   
Results 
Patient Profile: 
Consecutive patients who had adult renal transplantation between March 2007 to 
February 2008 and completed 9months of follow up by January 2009 were enrolled in the 
study. 
Figure 11.  Patient Profile of the Study 
 
Figure 12: Clinical Course During the Study 
Pre transplant   Transplant  Post Transplant Period 
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       Baseline                       2nd month            4th month           6th month            9th month 
 
CABP, Office BP                                       CABP, Office BP, Laboratory and Clinical Assessment.                                        
Laboratory, Clinical                                   Echocardiography at 9th month. 
ABPM Diary, Echocardiography  
50 patients were followed up prospectively for  9months. 
-3 patients were lost on follow up 
-2 patients had graft 
-1 patient died 
 Renal Allograft recipients-56 patients 
Demography Profile:  This study comprised of 50 patients who underwent live 
related renal transplantation (Table 6); of which 40 patients were male recipients and 29 
were female donors. Pre-transplant hypertension was 94% which had reduced to 72% 
post transplantation. The majority of the patients (86%) were on either two or more than 
two drugs while 14% were not on anti-hypertensives in the pre-transplantation period. In 
the post transplantation period 72% of the patient’s required anti-hypertensive medication 
and 28% of them required no anti-hypertensive drugs.  Mean duration of dialysis was 6±6 
months (median: 3.5months, Range: 0-28months) pre-transplant.   
Table 6 Demography Profile; n=50; *Mean ± SD, ** (Min-Max), ***n (%) 
Males: Females (Recipients) 40:10 (4:1) 
Males: Females (Donor) 21:29 (1: 1.3) 
**Donor’s Age(years), 40± 11.6 
**Recipient’s Age( years) 35± 11 
***Pre-Transplant DM 6 (12)  
***Post Transplant DM 11 (22) 
***Pre-Tx Hypertension 47 (94) 
***Post Tx Hypertension 36 (72) 
***Anti-HTN Drug Pre-Tx Nil:7 (14), ≤ 2drugs:30 (60), >2drugs: 13 (26) 
***Anti-HTN Drug Post-Tx Nil:14 (28), ≤ 2drugs:23 (46), >2drugs: 13 (26) 
*Duration of Dialysis in months 6 ± 6 
***HLA  <2 Ag Match: 16 (32), ≥2 Ag Match: 34 (68) 
***Induction Yes: 33(66), No: 17(34) 
*Warm Ischemic Time (min) 5.3 ± 6.6 
*Cold Ischemic Time (min) 70.2 ± 20.6 
 
Native Kidney Disease:  72% of the patient’s native kidney disease was unknown 
and 12% were diabetic nephropathy while 16% of them had other glomerular nephritis. 
 
Immunosuppression : 65% of the patients received induction either ATG of IL2 
prior to transplant. 90% of the patients received primary immunosuppresion as 
Prednisolone (Pred) +Tacrolimus (Tac) and Mycophenolate (MMF) while 2% of the 
patients received Pred+Tac and Azathioprine. One patient was serology positive for 
hepatits C and hence was on cyclosporine as part of his immunosuppressive protocol. A 
significant increase in the cumulative dose of steroids and Tacrolimus were noted over 
the post transplantation period. 
 
Figure 13: Native Kidney Disease
72%
12% 
6% 4% 4% 2%
Unknown Diabetic Nephropathy
FSGS Reflux/Obstructive
Others Ig A
Table 7 Immunosuppression 
 
 
Laboratory and Clinical Charateristics 
76% of the patients had no rejection, 24% had acute rejections of which 8% had one 
rejection episode, 12% had two rejection episodes and 4% had three rejection episodes. 
In these rejection episodes 11 episodes were acute cellular rejection (reversible with 
steroids) and two episodes were acute vascular rejection (steroid resistant but reversible 
with ATG). In the immediate transplant there was an increase in the BMI which remained 
stable in the remaining period of follow up. The office BP and the ABPM registries, renal 
function, albumin, 24hr proteinuria improved during the post transplantation period as 
represented. The office SBP and DBP, mean SBP and DBP, Awake SBP and DBP, 
Asleep SBP and DBP, Awake-Asleep SBP and DBP and MAP did not have any 
significant correlation with eGFR and creatinine at all time points.  
 
 
 
 
Immunosuppresion n (%) 
Pred+Tac+MMF 45 
(90) 
Pred+Tac+Aza 4 (8) 
Pred+CsA+Aza 1 (2) 
Immunosuppresion 2nd Month 4th Month 6th Month 9th Month 
Tacrolimus in ng/ml 328.3±89.4 619.7±171 890.6±274.9 1269.9±435.9
Steroid &Methyl  Pred 
(mg)  
1096.8±508.9 1760.2±524 2134.5±260.2 2951.6±357.2
Table 8. Laboratory Characteristics, n=50 
Characteristics Pre-TX 2nd Month 4th Month 6th month 9th month p value
Creatinine 4.7±1.4 1.1±0.2 1.2±0.2 1.2±0.2 1.2±0.2 0.0 
eGFR 15.9±5.1 75.6±17 71.6±18.7 71±17.3 69.5±16.7 0.0 
Albumin 3.6±0.5 4.3±0.3 4.4±0.4 4.4±0.4 4.5±0.2 0.0 
24hr Proteinuria 2338.5±2093.3 316.3±612 316.5±854.3 249±440 200.6±171 0.0 
 
Table 9: Clinical Profile 
Characteristics Pre-Tx 2nd Month 4th Month 6th Month 9th Month p value 
BMI  20.6±3.6 21.0±3 21.9±3.1 22.4±3 22.9±3.7 0.0 
SBP 140±16.1 120.3±9.7 120.1±11.3 120.7±9.2 120.1±9.4 0.0 Office 
BP DBP 88.2±8.9 82.1±7.6 78.7±7.6 78.7±7.2 79.4±6.7 0.0 
 
 
Table 10:ABPM Pre-Tx, 2nd, 4th, 6th, 9th month after transplantation, m ean±SD 
BP Readings Pre-Tx 2nd 4th 6th 9th p value
SBP 127.2±14.7 120±9.6 117.9±7.9 118.7±7.4 117.2±8.3 0.0 
SBP Awake 127.7±14.9 119.8±94 118.9±7.7 118.9±7.3 118.1±8.9 0.0 
SBP Asleep 124.6±16.3 120.3±11 117.6±9.6 117.8±8.4 116.9±9.3 0.0 
DBP 81.2±13.6 73.1±7.4 71.9±6.8 72.2±5.9 71.0±6.7 0.0 
DBP Awake 80.9±11.7 73.5±7.5 72.2±6.9 72.8±5.9 72.0±7.8 0.0 
DBP Asleep 77.2±12.3 72.5±8.2 70.9±7.6 71.4±7.1 69.9±7.0 0.0 
Awake-Asleep SBP 0.98±0.08 1.0±0.07 1.0±0.07 1.0±0.07 0.9±0.07 0.0 
MAP 65.5±13.6 57.5±8 56.5±7.9 56.8±6.8 55.6±7.5 0.0 
Awake-Asleep DBP 0.95±0.09 0.98±0.0 0.98±0.08 0.99±0.07 0.97±0.08 0.0 
Office and ABPM Before and After Renal Transplantation 
Concordance or Discordance between Office BP and ABPM-Derived BP 
Equivalence study (Table 10) for the comparison of times matched measurements for 
office and ABPM showed the upper confidence interval of 5-7units the maximum. At 
each time point the office measurement tend to overestimate the blood pressure by 22-
70% for SBP and DBP.  
Table 11: Comparison of Office and ABPM BP Measurements; Mean±SE  
Time Office CABP 95% CI t-value 
Systolic BP 
     Month 2: 
Month 4: 
Month 6: 
 
121.18± 1.55 
122.02±1.45 
121.09±1.35 
 
121.52±2.1 
119.27±1.71
117.96±1.22
 
-5.38 to 4.69 
-1.62 to 7.12 
-0.69 to 6.95 
 
1.42 
3.03 
3.65 
Diastolic BP 
    Month 2: 
Month 4: 
Month 6: 
 
80.9±1.09 
81.18±0.79 
79.88±0.80 
 
76.75±1.51 
76.16±1.29 
72.82±1.06 
 
0.56 to 7.74 
2.16 to 7.88 
3.96 to 10.15 
4.45 
6.18 
7.01 
Mean Arterial Pressure 
Month 2: 
Month 4: 
Month 6: 
 
67.47±1.15 
67.57±1.01 
66.14±0.80 
 
61.83±163 
61.79±1.38 
57.77±1.25 
 
1.79 to 9.48 
2.49 to 9.07 
4.79 to 11.95 
 
4.92 
5.83 
6.78 
 
Table 12: Risk factors for SBP and DBP 
A GEE analysis for the risk factors showed no significant predictors for the control of 
SBP, DBP and MAP.  
Risk Factors SBP, p value DBP, p value MAP, p value 
HLA 0.4 0.2 0.5 
Recipient Age 0.1 0.1 0.1 
Donor’s Age 0.6 0.5 0.6 
Rejection Episodes 0.6 0.9 0.5 
Recipient’s BM 0.4 0.2 0.4 
Proteinuria 0.3 0.7 0.7 
Creatinine 0.5 0.9 0.3 
WIT 0.7 0.3 0.9 
CIT 0.3 0.8 0.1 
Duration of Dialysis 0.6 0.8 0.4 
Donor’s DTP 0.8 0.7 0.6 
Donor’s Mean SBP 0.4 0.5 0.3 
Donor’s Mean DBP 0.2 0.3 0.2 
Baseline SBP of 
Recipient 
0.4 0.2 0.07 
Baseline DBP of 
Recipient 
0.2 0.3 0.06 
 
A Bland Altman plot (Figure 13) for similarity showed the tendency for the office to 
blood pressure to be overestimated when the ABPM readings were low and 
underestimate when the ABPM readings were high for SBP and DBP.  
 
Figure 14: Bland Altman Plot comparing the SBP, MAP and DBP of ABPM with 
Office BP Measurement 
 
 
 
Figure 15: SBP and DBPM of ABPM over time 
 
However the blood pressure control improved over irrespective of time and the number 
of drugs used at each time point. (Figure 14, 15) 
 
Figure 16: Relationship of SBP,DBP and MAP irrespective of drugs and Duration of 
Transplant 
 
 
 
Circadian Abnormalities Before and After Renal Transplantation 
Pre-Transplant 15(30%) patients were dippers, 29 (58%) patients were non-dippers and 6 
(12%) patients were inverted dippers. During the follow up period there was an initial 
decline of dippers to 16% at the 2nd month subsequently the dippers increased to 20% at 
4th month, 24% at 6th month to 28% at the 9th month. However there was an increase in 
the non-dippers to 72% at the 2nd month followed by a gradual decline to 66% in the 
fourth and sixth month to 60% at ninth month. The inverted dippers fluctuated between 
12%-14% from pre-transplant to their last follow up at the 9th month.  
A sub-analysis (Table 13) of these three groups of patients showed among the true 
dippers at pre-transplant only six patients (40%) continued to be dippers at the 9th month 
while another six patients (40%) had become non-dippers and three patients (20%) 
became inverted dippers. Among the true dippers only one patient maintained its dipping 
status throughout the follow up period.  Among the true non-dippers at pre-transplant 
twenty patients (68%) continued to be non-dippers, seven patients (24%) had become 
dippers and two patients (8%) had become inverted dippers at 9th month after renal 
transplantation. Among the true inverted dippers four patients (66%) had become non-
dipper, one patient (16.6%) had become dipper and one patient (16.6%) continued to be 
an inverted dipper at the 9th month post transplant.  
Despite a successful renal transplantation and a good control of blood pressure, 68% of 
the patients maintained their non-dipping profile as 40% of them had a persistent high 
morning surge at 9th month post renal transplantation.  
Table 13.Dipper vs Non-Dipper vs Inverted Dipper Before and After Tx ;n(%) 
Characteristics PreTransplant 2nd month 4th month 6th month 9th month 
Dipper 15 (30) 8 (16) 10 (20) 12 (24) 14 (28) 
Non-Dipper 29 (58) 36 (72) 33 (66) 33 (66) 30 (60) 
Inverted 
Dipper 
6 (12) 6 (12) 7 (14) 5 (10) 6 (12) 
78% had the normal circadian rhythm and 22% had an abnormal circadian rhythm of 
their blood pressure at pre-transplant. During the post transplantation period at various 
time points there was mild improvement in the normal circadian rhythm for blood 
pressure with 84% at 9th month.  
Table 14. Circadian Rhythm Profile; n=50, n(%) 
 
Though there was improvement in the circadian rhythm profile (Table 14,15) of the 
patients, the non-dipping profile from 71.8% at pre-transplant reduced to 69% at 9th 
month of post transplantation. Among the non-dippers who had no improvement of their 
circadian rhythm 40% of them had a persistent high morning surge of their blood 
pressure at 9th month. Most importantly, the dipping profile in this cohort had improved 
from 12.8% at pre-transplant to 16.8% post transplant. This would be due to the reduction 
of morning surge in 25% of pre-transplant true dippers to 21% at 9th month of post 
transplantation. Isolated nocturnal hypertension was present in 16(32%) of the patients 
pre-transplant which reduced to significantly during the follow up to 7(14%) patients at 
2nd month, 4(8%) at 4th month, to 2(4%) by the 6th and 9th month post transplant. In this 
group the true non-dippers 12(41.4%) who had nocturnal hypertension at pre-transplant 
made a significant improvement over the period time with the incidence reducing to 3.3% 
at 9th month of post transplant 
Characteristics Pre TX 2nd month 4th month 6th month 9thmonth 
Normal Circadian 
Rhythm 
39 (78) 47 (94) 45 (90) 47 (94) 42 (84) 
Abnormal Rhythm 11 (22) 3 (6) 5 (10) 3 (6) 8 (16) 
Table 15.Circadian Rhythm and Dipper Profile n= 50, n(%) 
Pre-transplant 9th month Post Transplantation Circadian 
Rhythm Dipper Non Dipper Inverted 
Dipper 
Dipper Non 
Dipper 
Inverted 
Dipper 
Normal 5 (12.8) 28 (71.8) 6 (15.4) 7 (16.7) 29 (69) 6 (14.3) 
Abnormal 10(90.9) 1 (9.1) - 7 (87.5) 1 (12.5) - 
 
Predictors of Circadian Rhythm Abnormalities 
In those patients with an improved diurnal BP rhythm with a non-dipping profile an 
univariate linear regression analysis (Table 16 & 17) with the following risk factors: 
recipient age, duration of dialysis, pre-transplant and post transplant diabetes and 
hypertension, eGFR, creatinine, recipient BMI, mean SBP, DBP, Awake SBP and DBP, 
Asleep SBP and DBP showed mean SBP and DBP, Awake SBP and DBP at 9th month of 
post renal transplantation were significant (p≤ 0.05). However a multivariate regression 
analysis showed none of these risk factors were independent predictors to normal 
circadian rhythm of blood pressure. 
 
 
 
 
 
 
 
         Table 16. Univariate Analysis                    Table 17. Multivariate Analysis            
   
Pre transplant Post transplant 
Risk factors p   Risk Factors p  
Recipient Age 0.9 Recipient Age 0.4 
Recipient BMI 0.1 Recipient BMI 0.6 
 Dialysis Duration 0.7 DM 0.2 
DM 0.9 Hypertension 0.7 
Hypertension 0.7 Mean SBP 0.04 
Mean SBP 0.08 Mean DBP 0.02 
Mean DBP 0.1 Creatinine 0.9 
Creatinine 0.6 eGFR 0.8 
eGFR 0.9 Awake SBP 0.002 
Awake SBP 0.8 Awake DBP 0.004 
Awake DBP 0.06 Asleep SBP 0.8 
Asleep SBP 0.4 Asleep DBP 0.8 
Asleep DBP 0.8   
 
LVH,LVM and LVMI before and after Renal Transplantation 
There was significant reduction in LVH from 24 (48%) at pre-transplant to 9(18%) at 9th 
month of post transplant. On gender basis as per the criteria LVH was noted to be 
20(40%) in men and 4(8%) in women which had reduced to 5 (10%) in men and 
remained the same for the women after renal transplantation.  Among the women two 
Risk factors p 
value 
Post Tx Mean SBP 0.9 
Post Tx Mean DBP 0.9 
Post Tx Awake SBP 0.9 
Post Tx Awake DBP 0.9 
patients who had pre-transplant LVH continued to have LVH and two new patients with 
LVH pre-transplant had developed LVH. The LVM pre-transplant was 197.2 ± 68.5 
which reduced to 167.4±41.2 The LVMI at pre-transplant was 128.3±63.4 and at 9th 
month of post transplant was 101.2±24.2. There was a reduction of 30% in LVM and 
27% reduction in the LVMI at 9th month post transplant. 
Table 18. LVH, LVM, LVMI before and after transplantation; mean±SD, n(%) 
Characteristics Pre-TX Post TX-9th month p value 
LVH 24 (48) 9 (18) 0.05 
LVM 197.2±68.5 167.4±41.2 0.01 
LVMI 128.3±63.4 101.2±24.2 <0.05 
∆LVMI 9.3±36.0 0.07 
 
Risk Factors for LVM, LVMI and ∆LVMI 
To study the influence of recipient age, duration of dialysis pre-transplant, pre-transplant 
and post transplant diabetes mellitus, hypertension, creatinine and eGFR, no of anti-
hypertensive drugs and the 24hr BP levels we analyzed for positive predictors for LVM 
and LVMI at pre-transplant and 9th month of post renal transplantation. A univariate 
analysis (Table 19) showed pre-transplant BMI, duration of dialysis, diabetes mellitus, 
number of anti-hypertensive drugs, creatinine, eGFR, mean DBP and asleep DBP at pre-
transplant were significant for LVM. For LVMI except for pre-transplant diabetes 
mellitus the other risk factors were significant at pre-transplant. At 9th month of post 
transplant a univariate analysis showed significant correlation for duration of recipient 
age, BMI, post transplant diabetes and hypertension, creatinine, eGFR duration of 
dialysis, number of anti-hypertensive drugs, mean DBP and asleep DBP to be significant 
for LVM and LVMI.  However for ∆LVMI in addition to duration of dialysis pre-
transplant, age of the recipient, number of anti-hypertensive drugs at 9th month; 24hr BP 
registries such as mean SBP and mean awake and asleep SBP were significant. 
 
Table 19.Univariate Analysis for LVM,LVMI before and after transplantation at 9th 
month; p value 
Risk Factor Pre-Tx LVM 
 
Pre-Tx LVMI 
 
Post Tx LVM 
 
Post Tx LVMI 
Recipient Age 0.8 ≤0.05 ≤0.05 ≤0.05 
Recipient BMI ≤0.05 ≤0.05 ≤0.05 ≤0.05 
Duration of Dialysis 0.2 ≤0.05 ≤0.05 ≤0.05 
Pre Tx & Post Tx DM 0.04 0.07 ≤0.05 ≤0.05 
Pre Tx & Post Tx HTN ≤0.05 ≤0.05 ≤0.05 ≤0.05 
Anti-Hypertensive drugs ≤0.05 ≤0.05 ≤0.05 ≤0.05 
 Creat at Pre and Post ≤0.05 ≤0.05 ≤0.05 ≤0.05 
eGFR at Pre and Post ≤0.05 ≤0.05 ≤0.05 ≤0.05 
Mean SBP 0.02 ≤0.05 0.8 0.8 
Mean DBP ≤0.05 ≤0.05 0.03 0.04 
Mean Awake SBP 0.04 ≤0.05 0.7 0.6 
Mean Awake DBP 0.04 ≤0.05 0.06 0.04 
Mean Asleep SBP 0.02 ≤0.05 0.1 0.3 
Mean Asleep DBP ≤0.05 ≤0.05 0.02  ≤0.05 
A multiple linear regression (Table 20) of these significant factors at these two time 
points showed that duration of dialysis pre-transplant, post transplant hypertension and 
number of anti-hypertensive drugs at 9th month were positive predictors at the 9th month 
of post transplantation for LVM and LVMI. No predictors were significant at pre-
transplant for LVM and LVMI. At 9th month duration of dialysis pre-transplant was 
significant for ∆LVMI. 
Table 20.Multivariate Analysis of LVH after renal transplantation at 9th month 
Risk Factor LVM LVMI ∆LVMI 
Duration of Dialysis Pre-Transplant 0.04 0.04 0.04 
Post Transplant Hypertension ≤0.05 ≤0.05 0.3 
No: Antihypertensive Drugs at 9th month 0.03 0.001 0.9 
 
Discussion 
Hypertension is a powerful predictor of renal transplant outcome; however, accurately 
diagnosing high BP remains a challenging task in renal transplant recipients. Several 
previous studies in renal transplant patients have shown abnormal ABPM hypertension-
diurnal rhythm. The incidence and predictors of hypertension-abnormal diurnal BP 
rhythm in this patient population remain unclear. Majority of the studies have been done 
on a cyclosporine population and very few data available on a tacrolimus population in 
adult renal transplantations though data are available in the pediatric renal recipients. 
What has been lacking to date is a large-scale study of these issues in renal transplant 
patients in India.  
 
This is a study which has prospectively analyzed the diurnal BP rhythm profiles from 
dialysis to engraftment, a difference in the categorization of patients as normotensive and 
hypertensive subjects by the use of ABPM and to see the comparison of office BP with 
ABPM. In this study we also analyzed the effects of a successful renal transplantation 
and BP on the morphology of the left ventricle as evaluated by Doppler 
echocardiography, particularly the influence of various risk factors on the development of 
LVM, LVMI and ∆LVMI.  
 
Our data demonstrate an over estimation of office blood pressure at all time point when 
compared to ABPM. The difference range from 4-7mmHg of SBP and DBP of office BP 
vs. ABPM.  At each time point the office blood pressure overestimates 22%-70% in our 
study. A problem with ABPM measurement is that the definitions of “normal,” thresholds 
for intervention, and targets for treatment are all less well defined than for clinic BP. A 
review of literature shows the degree for office BP to overestimate ABPM measurements 
varies in each study undertaken. Authors opine a difference of 4-7mmHg to 10/5mmHg 
in their respective studies. 115,116,117 Unfortunately, no algorithm or regression equation 
can be determined from comparative studies, because ABPM is both underestimated and 
overestimated by CBP measurements.117,161 Overestimation may be attributable to white-
coat hypertension or to a normal nocturnal dipping, whereas underestimation could be 
explained by the fact that the studied patients take their antihypertensive medication 
shortly before the CBP morning measurement 117,161 or because they have a high 
nocturnal BP level. Possibly, more often, mean 24-hr BP levels, as determined by ABPM, 
exceed CBP levels 
 
This study did not show the presence of any risk factor like recipient’s age, duration of 
dialysis, pre-transplant hypertension and diabetes, HLA mismatches, rejection episodes, 
cumulative dose of steroids and tacrolimus, induction, pre-transplant BMI, pre-transplant 
creatinine and GFR, WIT and CIT, baseline SBP and DBP by GEE analysis for the 
control of blood pressure after taking into the consideration of the confounding factor 
such as number of anti-hypertensive drugs. This study showed that the blood pressure 
remained under good control over time irrespective of the number of anti-hypertensive 
medications showing that number of drugs can predict the severity in controlling the 
blood pressure but not the variability of the blood pressure in the diurnal rhythm of blood 
pressure control as shown with a wide variation in the standard error of the mean SBP, 
DBP and MAP readings in the 24hr ABPM(Figure 13&15).  There was also no 
significant correlation of ABPM registries in relation to renal function in our study and 
target organ damage. This could be possible due to the fact that the target organ damage 
and alteration in renal function can be correlated only in a long term follow up of patients 
which is a limitation in our study. Unlikely in Jacobi et.al and Covic et.al who showed 
the baseline creatinine and 24hr SBP and DBP had significant impact on graft failure who 
were followed up for 5years.115,161  
 
Studies in adults describing the immediate impact of successful renal transplantation on 
the circadian BP profile and BP variability are few. Our study showed a significant 
improvement of circadian rhythm of blood pressure from 74% to 94% in the immediate 
post transplant period and subsequently to 84% at 9th month of post renal transplantation. 
This could be due to three reasons; firstly, the significant reduction in the nocturnal 
hypertension from 32% to 16% at 2nd month and subsequently to 4% by the 9th month 
among the pre-transplant non-dippers with nocturnal hypertension (41.4%) to   3% at 9th 
month. Secondly the use of tacrolimus immunosuppresion than a CsA based regime. 
Thirdly, probably due to an aggressive control of blood pressure. A univariate analysis 
showed mean SBP, DBP and awake SBP and DBP were positive predictors for a normal 
circadian rhythm. None of these factors were significant on multivariate analysis. At the 
same time, diurnal variation was not influenced by: duration of dialysis, pre-transplant 
diabetes and hypertension number of rejection episodes or HLA, mismatches, type of 
antihypertensive medication.  
 
Our result was contradictory to the studies which showed a worsening of circadian 
rhythm of blood pressure in the immediate transplant period the main reason being that 
most of the studies done of 24hr ABPM have been assessed on cyclosporine based 
immunosuppressive regime and ours have been a 94% tacrolimus based 
immunosuppressive regime. Data on the influence of tacrolimus in renal transplant 
population on 24hr BP profile are less where the incidence of nocturnal hypertension, 
non-dipping status, variability in circadian rhythm are less in tacrolimus when compared 
to CsA.162 Majority of the studies have been on pediatric and liver transplant recipients.  
Hence more control studies are required to study the anti-hypertensive effect of CsA and 
Tacrolimus. A study was performed by Fereira et al. in which 24 patients with ESRD 
were prospectively studied by ABPM before and at 3, 6, and 12 months after renal 
transplantation (CsA/Pred/MMF regime). A significant drop in the mean values of 
daytime and nocturnal systolic blood pressure at 12 months after transplantation was 
recorded. All patients were non-dippers before transplantation, but only two patients 
(8.3%) were dippers, 12 months after transplantation. Patients were randomly selected 
from the center’s living related program, but it is not clear if this was not a particular 
subgroup population, when we take into account the rather unusual 80%-100% 
nondipping prevalence before transplantation. 
A prospective study by Covic et.al where 20 consecutive renal allograft recipients    
( CsA/Pred/MMF)  were  analyzed. This study showed severe worsening of the circadian 
profile, at 1 month following renal transplant, when all subjects are non-dippers, 80% 
having in fact higher nocturnal BP compared to diurnal levels which did recover to a 
normal circadian profile in one third of the initial pre-transplant non-dippers in the late 
transplant period.  They also showed that in the immediate transplant there were no 
predictors for circadian variability but late transplant period diurnal variation was only 
influenced by the age of the recipient and eGFR at post transplant period.164 Faria et.al 
and Ligtenberg et.al should a significant initial worsening of circadian rhythm of blood 
pressure with a tendency towards attaining a normal rhythm over time for patients on 
CsA when compared to Tacrolimus.162,165 This could also be a reason in our study to 
show a low incidence of abnormal circadian variability and nocturnal hypertension in the 
immediate transplant  period as shown in other studies where in predominant 
immunosuppresion were CsA based regime and load of immunosuppresion is high. Over 
time as the immunosuppresion is tapered the incidence of non-dipping reduces with an 
improvement of circadian variability as reported by these same studies on their follow 
up.162, 165 
 
In the study of Gatzka et al., the prevalence of dippers increased from only 27% in the 
early post transplant phase to 73% in the late phase (>1 year); this effect was independent 
of the level of mean 24 hr-BP and of the antihypertensive and immunosuppressive 
medication.166 Our data showed no significant change in the dipper status. Despite a 
successful renal transplantation and a good control of blood pressure 68% of the patients 
maintained their non-dipping profile at all time points and the dipper status improved 
marginally suggesting the need for a longer duration of follow up and ABPM.   
 
After more than 1 year following transplantation, the major determinants of the circadian 
variability are the level of the renal function, and the initial dipping profile. Covic et.al 
reported 55% at one year post renal transplantation.161, 164 In our cohort no significant 
predictors of the circadian variability and non-dipping status were identified. This 
observation, coupled with the fact that a significant proportion of patients maintain their 
nondipping profile unchanged, suggest that some changes are irreversible despite 
successful renal transplantation and a well controlled blood pressure profile during the 
post renal transplantation period and would require a long term follow up. 
 
LVH is the main feature found in chronic uremia, being present in 75% of patients who 
begin ESRD therapy. It is considered an independent cardiovascular risk factor, which 
significantly raises the chance of sudden death, heart failure, coronary artery disease, and 
cardiac arrhythmias. Our study showed a 30% reduction in LVH with corresponding 30% 
and 27% reduction in LVM and LVMI. This had a beneficial outcome on LVH Studies in 
literature show a significant change noticed only after one year post transplantation. The 
use of CsA based regime as demonstrated by Lipkin et al. in his study of ambulatory 
blood pressure and left ventricular mass in cyclosporine and non-cyclosporine treated 
renal allograft recipients found a nondipping pattern more frequently among cyclosporin 
treated patients and associated with a higher left ventricular mass.  The improvement in 
LVH could be attributed to the use of tacrolimus regime in our population. Association of 
risk factors (Table 18, 19) with single and multiple regression analysis showed that the 
duration of dialysis, number of anti-hypertensive drugs post transplant and post transplant 
hypertension were significant predictors for reduction in LVM and LVMI and duration of 
dialysis was significant predictor for ∆LVMI. The significance increase number of anti-
hypertensive drugs  can be an indirect predictor of the severity of post transplant. Our 
study did not show any significant BP measures (Office of ABPM) as reported by 
studies134,161,164 in literature; probably due to the good control of blood pressure, lowest 
immunosuppresion with therapeutic drug monitoring at post transplant at all time points 
of follow up. 
The value of ABPM in renal transplant recipients will be adequately appreciated only 
when a randomised trial is undertaken, with BP therapy decisions based on ABPM versus 
office BP measurements, in matched cohorts, and with graft survival and major adverse 
cardiovascular events as hard endpoints. 
Conclusions 
In renal allograft recipients from India the study concluded that: 
1. Office BP measurements (SBP and DBP) tend to record higher when ABPM records 
lower readings and lower readings are recorded by Office BP when the ABPM 
readings are higher. The difference being 4-7units of mmHg. 
2. Blood pressure was well controlled in the post transplantation period  with multiple 
variable drugs. 
3. Office and ABPM measurements did not correlate with renal function in the early 
post transplant period. A longer duration of follow up is required to see the 
association of BP measurements in our population. 
4. No significant risk factor was  associated with the blood pressure variability, diurnal 
rhythm of BP,  and dipping status in our population 
5. There was mild improvement of circadian rhythm noted in early transplant period the 
variability of diurnal rhythm in late transplant period requires a longer duration of 
follow up.  
6. A significant reduction in nocturnal hypertension among the true non-dippers was 
noticed in this study at early transplant.  
7. Duration of dialysis, post transplant hypertension and the number of anti-hypertensive 
drugs at post transplant are positive predictors in reduction of LVM, LVMI and 
improvement in ∆LVMI. 
 
 
 
Thesis Proforma 
 
Name of Recipient:           
Hospital No:         
Addresses: 
Phone Number:             e-mail: 
Sex:             
1. M   2. F      
 
Age of Recipient:    Date of Transplant:          
Relationship: 
1. Parents 
2. Siblings 
3. Children 
4. Spouse 
5. Other: Cousin, Aunt, Uncle, Grand 
Donor’s Age 
1. >20≥30 
2. >31≥40 
3. >41≥50 
4. >51 
 
 
Donor’s Sex: 
   Female -0 / Male -1 
Donor HT:        Donor Weight: 
Donor DTPA GFR before Transplant: 
Pre Tx DM :  No – 0   /   Yes – 1 
Pre TX HTN:  No – 0   /   Yes – 1 
Preemptive TX: No – 0   /   Yes – 1 
Duration of Dialysis in months: 
Cross Match: 
 Neg – 0/ Pos <5% - 1 / Pos 5-20% - 2 / Pos >20% - 3 
HLA:  
Nil -0 
Single Ag(A or B) -1 
Single Ag +DR -2 / Haplo – 3 
3 Ag match – 4  
Full – 5. If more than 1 Ag matches to fill below details: 
• A: 1/2 
• B:1/2 
• DR:1/2 
• DQ:1/2 
Native Kidney Disease 
1. Unknown 
2. FSGS 
3. Diabetic Nephropathy 
4. Ig A Nephropathy 
5. Reflux/Obstructive Nephropathy 
6. Membranous nephropathy 
7. Mesangial Proliferative GN 
8. Others: Cresentric GN, Lupus Nephritis, Vasculitis 
Induction:  Induction: Nil  – 0 / Simulect – 1 / ATG – 2  /  Daclizumab – 3  /  Others – 4 
Warm Ischemia Time (min): 
Cold Ischemia Time (min): 
Blood transfusion before transplant: 
1.  Nil   
2.  ≤2pints 
3.  >2≤5 pints 
4.  >5pints 
 
No: of Anti-hypertensive drugs before transplant: 
1. Nil drugs 
2. ≤2 drugs 
3. >2 drugs 
No: of Anti-hypertensive drugs after transplant with CNI: 
1. Nil drugs 
2. ≤2 drugs 
3. >2 drugs 
Type of Immunosuppression: 
1. Prednisolone: No -0  /  Yes -1 
2. Cyclosporin: No -0  /  Yes -1 
3. Tacrolimus: No -0  /  Yes -1 
4. Azathioprine:  No -0  /  Yes -1 
5. MMF:  No -0  /  Yes -1 
6. Sirolimus: No -0  /  Yes -1 
7. Everolimus: No -0  /  Yes -1 
 
Duration of follow up (Last Visit) in Months: 
 
Dose of Immunosuppresion (AUC) at various time points: 
 
 0month 2month 4month 6month 12month 
Tacrolimus      
Cyclosporine      
Cumm Steroids      
 
 
 
 
 
 
CLINICAL DATA 
 
Anthropometric Measurements of recipient: 
 
Ht:           cms Ht: cms WT: Kg BMI 
Pre-Tx Wt0/BMI0    
2month Wt2/BMI2    
4month Wt4/BMI4    
6month Wt6/BMI6    
9-12mth t12/BMI12    
 
Blood Pressure Monitoring 
 
Office BP at the time of CABP 
 
Date SBP1 SBP2 SBP3 DBP1 DBP2 DBP3 
2nd mth       
4th mth       
6th mth       
9th-12thmth       
 
 
 
CABP: DT-Day time, NT-Night Time 
 
Date 24hr 
Syst 
24hr 
Dias 
DT 
Sys 
DT 
Dias 
NT 
Sys 
NT 
Dias 
Ratio of 
NSBP:NDBP 
Ratio of 
DSBP:DDBP 
2nd mth         
4th mth         
6th mth         
9th-12thmth         
 
Normal Circadian Rhythm: Sleep: Awake Ratio :> 0.92(SBP) and >0.9(DBP) 
1. Yes 
2. No 
 
Dipper/Non-Dipper Status 
1. Dipper(0.8-0.9) 
2. Non-Dipper(0.9-1) 
3. Inverted Dipper(>1) 
 
Left ventricular Mass 
 
 LVM LVMI ∆LVMI 
Pre-Transplant    
9th Post Tx    
Investigation Profile at the time of CABP 
 Sr.Creat eGFR Sr.Alb 24hr.Prot Lipids 
Pre-Tx      
2nd mth      
4th mth      
6th mth      
9-12th mth      
Last Visit      
 
No. of Rejection episodes: 
Num     
Date     
Acute / chronic     
Vascular / cellular     
Type     
Rx 
No-0 
MePred3 -1 
ATG -2 
OKT3-3 
    
Response 
Nil -0 / Parital-1  / Full -2 
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